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Hepatocellular carcinoma (HCC) is one of the most deadly cancers in 
the world. The poor prognosis of patients is due to recurrence of HCC, 
resulting in cancer-related death of early stage HCC patients. Staging systems 
do not provide sufficient information to predict the risk of recurrence. This is 
compounded by the lack of adjuvant therapies available for prevention of 
recurrence. Hence, there is an urgent need to identify prognostic biomarkers 
which would guide patient management and provide new leads for 
development of novel therapies. In the discovery phase of the study, we 
employed iTRAQ labelling combined with 2D-LC-MS/MS to interrogate the 
proteome of the tumour and the adjacent non-tumour liver tissues of two 
groups of stage I HCC patients: patients experiencing early recurrence (ER) 
within two years of resection and patients who were recurrence-free within 
two years of resection (NR). A total of 52 proteins were identified to be able to 
segregate the patients according to their recurrence status. Among these 
proteins, an increased upregulation of DNPH1 and HSP10 expression was 
observed in the tumours of ER patients compared to NR patients. The 
expression patterns of DNPH1 and HSP10 were first validated using SWATH-
MS, and subsequently by western blot in a larger cohort of patient samples.  
DNPH1, a downstream target of c-Myc, has been regarded as a 
potential therapeutic target for cancer. However, the biological function of 
DNPH1 in cancer development is unknown. Hence, functional studies were 
performed to evaluate the role of DNPH1 in HCC. Stable knockdown of 
DNPH1 in Hep3B cells resulted in a decrease in migration and invasion, with 
x 
 
no significant changes in proliferation. To further understand the biological 
processes affected by DNPH1 expression, a comparative proteomics study was 
performed between DNPH1 knockdown cells and scrambled control cells 
using iTRAQ labelling approach. iTRAQ analysis revealed changes in 
expression of metastasis-related proteins involved in invadopodia formation 
and maturation. In addition, we also observed changes in expression of 
proteins involved in redox modulation, lipid metabolism and electron transport 
chain complex formation. These three groups of proteins could potentially 
interact with each other to modulate inflammatory pathways, which might 
affect the metastatic potential of HCC cells indirectly. Overall, our study is the 
first to establish the potential role of DNPH1 in HCC metastasis. Comparative 
proteomics via iTRAQ provided insights to the different biological pathways 
affected by DNPH1 expression. DNPH1 may also be considered as a possible 
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CHAPTER 1 INTRODUCTION   
1.1 Hepatocellular Carcinoma (HCC) 
1.1.1 Epidemiology of HCC  
Hepatocellular carcinoma is the most common form of primary liver cancer, 
accounting for 83% of all liver cancer cases. It is the fifth most prevalent 
cancers in the world, with an estimated 700,000 new cases being diagnosed 
yearly [1]. However, it is the second most deadly cancer, with a high mortality 
to incidence rate of 0.95. The trend is similar in Singapore, of which it is the 
fourth most frequent cancer, and the third highest cause of cancer related death 
in males [2]. Hence, HCC is a major health concern, with most of the patients 
suffering from a poor prognosis.         
The risk factors for HCC are well established. Chronic Hepatitis B (HBV) and 
C (HCV) viral infections are the most prominent causes of HCC, which 
account for 70% of all HCC cases worldwide [3]. Other common causes of 
HCC include chronic alcoholism, ingestion of aflatoxin-B1 contaminated food, 
non-alcoholic fatty liver disorder (NAFLD) and non-alcoholic steatohepatitis 
(NASH). Certain medical conditions also predispose patients to a higher risk 
of HCC. Patients with hereditary haemochromatosis exhibit higher iron levels 
in the liver cells, which promote liver damage by increasing oxidative stress 
and DNA damage [4]. Insulin resistance and related free fatty acid and 
triglyceride accumulation in the liver promote hepatic steatosis in diabetic 
patients, which leads to hepatocellular injury, cytokine induction and 
inflammation [5]. Overall, most of the risk factors for HCC can contribute to 
cirrhosis of the liver.   
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The different risk factors are correlated to the geographical locations. HCV 
infection and chronic alcohol abuse are more prevalent in North America, 
Europe and Japan [6], while HBV infection is highly prevalent in East Asian 
countries [7]. Chronic HBV infection is also the commonest cause of primary 
HCC in Singapore. Aflatoxin-B1 associated HCC is more frequently observed 
in developing countries such as Africa and China, where aflatoxin-B1 
contamination of food remains a serious problem due to poor hygiene [8]. The 
multitude of aetiological factors may affect the pathways involved in 
development of HCC, resulting in high genetic heterogeneity of tumours 
despite being considered as a single disease entity.   
1.1.2 Histopathological progression of HCC  
Hepatocarcinogenesis is a multistage and multifactorial process involving 
numerous genetic alterations leading to the development of cancer. However, 
the process of carcinogenesis in HCC is poorly understood, due to the 
numerous risk factors which may result in HCC progression through different 
pathways. Nonetheless, the pathogenesis of HCC can be tracked by observing 
the morphological changes of the hepatocytes occurring during 
hepatocarcinogenesis (illustrated in Figure 1-1). All the aetiological factors of 
HCC result in injury to the liver, abeit via different mechanisms. This results 
in the activation of the necrosis-regeneration cycles, which promotes the 
formation of an inflammatory microenvironment by recruitment of immune 
cells and persistent expression of inflammatory cytokines. The activated 
inflammatory cells promote the release of reactive oxygen species (ROS), 
which results in damage to biomolecules such as DNA, resulting in genetic 
mutations. This chronic inflammatory state will cumulate into the formation of 
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a cirrhotic liver, which is characterized by abnormal liver nodule formation 
and collagen deposition. In time, these abnormal liver nodules can progress to 
form dysplastic nodules. The pro-inflammatory environment promotes the 
accumulation of genetic aberrations of hepatocytes, leading to the 
transformation from dysplastic nodules into early HCC. Early HCC tumours 
are usually well differentiated and the cells become more dedifferentiated as 
they progress, losing most of the liver related functions and gaining multiple 
malignant traits which promote high proliferation and metastatic potential of 
the late stage HCC cells [9]. These progressed HCC cells are usually poorly 







Figure 1-1: Histopathological progression of HCC. Injury to hepatocytes caused by any of the aetiological factors results in the death 
of the hepatocytes. The liver responds to cell death by promoting proliferation of hepatocytes, and recruitment of inflammatory cells. 
Persistent injury-proliferation cycles lead to liver cirrhosis, characterized by formation of abnormal liver nodules and scarring. The 
inflammatory background of the cirrhotic liver also results in the accumulation of genetic aberrations in hepatocytes. In time, the dysplastic 
nodules will form HCC, which will become more dedifferentiated as it progresses to a more malignant stage. Figure adapted from Farazi et 
al., 2006 [10], with minor modifications.      




1.1.3 Surveillance and diagnosis of HCC  
The preferred method for surveillance of HCC is ultrasonography, which is 
widely available and recommended for high risk patients, such as those with 
cirrhosis and chronic HBV infection [11]. Ultrasonography is well tolerated by 
most people and should be performed every 6 months for surveillance 
purposes.  Diagnosis of HCC is usually performed using non-invasive imaging 
methods, such as dynamic multiphase contrast-enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI). The imaging method 
is based on the hypervascularity of the liver tumour compared to the 
surrounding parenchyma, and is widely applicable to patients with or without 
cirrhosis. Nodules of 2 cm or more are diagnosed by the intense contrast 
uptake during the arterial phase, followed by washout in the portal and 
delayed phases [11, 12] detected using dynamic MRI or multidetector CT. If 
the nodule does not exhibit typical imaging pattern using a single imaging 
method, an alternative imaging modality can be used to confirm the diagnosis 
of HCC. If both imaging methods fail to provide conclusive evidence, a 
diagnostic biopsy can be ordered. However, the false negative rate of biopsy 
can be as high as 30% due to sampling error or absence of typical features of 
HCC [13]. The diagnosis of HCC can be improved by the use of 
immunohistochemical staining of panel of 4 biomarkers, namely glypican 3, 
clathrin heavy chain, glutamine synthetase and heat-shock protein 70 [14]. 
This panel of biomarkers has a high specificity but low sensitivity, which aids 




1.1.4 Staging systems for HCC  
Staging systems provide a platform for evaluation of tumour burden in the 
primary organ and its spread throughout the body. They also allow for 
prognostic stratification and guiding of suitable treatment modalities based on 
the severity of the disease. The staging of liver cancer should also include the 
function of the residual liver, since most of the tumours develop from a 
cirrhotic liver background. The presence of a unified staging system would aid 
clinical research in selection of a homogenous patient group for various 
studies. However, due to the vast heterogeneity in aetiological factors, there is 
no consensus in the best staging system to be used in HCC. Two of the 
commonly used staging systems will be discussed here. The Barcelona Clinic 
Liver Cancer (BCLC) staging system is the standard system used by the 
American Association for the Study of Liver Disease [11] and European 
Association for the Study of the Liver [15]. There are four main elements to 
the staging system: tumour extension, liver functional reserve, physical status 
and cancer related symptoms. The patients are then classified into one of the 5 
categories (0, A, B, C, D) based on these 4 elements. In addition, the BCLC 
staging also provides a guideline for the recommended treatment to each 
patient based on the categories in which they are assigned to. The BCLC 
staging system has its limitations. Firstly, it is unable to provide accurate 
prognosis of intermediate stage (stage B) patients, which consisted of a large 
group of patients with huge variation in the 4 elements as stated above. 
Secondly, it may be difficult to follow the rigid treatment recommendation in 
actual clinical practice. The flow in categorizing patients based on BCLC is 






Figure 1-2: BCLC staging system. The system relies on the evaluation of 4 elements; tumour characteristics (size, number and presence 
of portal invasion or extrahepatic metastasis), liver function (Child-Pugh A to C), Physical status (PS 0 to 4) and presence of associated 
diseases. Patients are divided into 5 different stages based on the combination of the 4 elements. Treatment options are provided for patients 
in different BCLC stage. Figure adapted from Forner et al., 2012 [6].      
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The other commonly used staging system is the Tumour-Node-Metastasis 
(TNM) classification (Table 1-1) developed by American Joint Committee on 
Cancer (AJCC) [16]. This staging system assesses the tumour features (T), 
lymph node involvement (N) and distant metastasis (M). The TNM staging 
provides a comprehensive histopathological assessment of the primary tumour. 
However, there is no information to guide treatment, and this system does not 
take into consideration of the function of the residual liver, hence providing 
little prognostic power for advanced stage patients.  
Table 1-1: AJCC TNM staging for Liver Tumours (7th Edition, 2010) [16]   
Primary Tumour              
TX Primary tumour cannot be accessed  
T0 No evidence of primary tumour 
T1 Solitary tumour without vascular invasion  
T2 Solitary tumour with vascular invasion or multiple tumours no 
more than 5 cm 
T3a Multiple tumours more than 5 cm 
T3b Single tumour or multiple tumours of any size involving a 
major branch of the portal vein or hepatic vein  
T4 Tumours with direct invasion of adjacent organs other than the 
gallbladder or with perforation of visceral peritoneum  
Regional lymph nodes (N)           
NX 
Regional lymph nodes cannot be 
accessed  
  N0 No regional lymph node metastasis 
  N1 Regional lymph node metastasis      
Distant Metastasis (M)             
M0 No distant metastasis  
   M1 Distant metastasis  
    Anatomic stage/prognostic groups          
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage IIIA T3a N0 M0 
Stage IIIB T3b N0 M0 
Stage IIIC T4 N0 M0 
Stage IVA Any T N1 M0 




There are other staging methods available, such as Okuda [17], CLIP [18], 
CUPI [19] and JIS [20] score. Each staging system has its own strengths and 
limitations in providing prognostic information. However, these staging 
systems were developed from clinical data obtained within the individual 
countries. The differences in aetiology of HCC for the patients in different 
geographical locations may limit the effectiveness of the staging system when 
applied to a different cohort. There is no perfect staging system yet available 
for HCC. Hence, it is difficult to obtain accurate prognostic information of 
HCC patients based solely on the application of a single staging system.   
1.1.5 Curative treatment for HCC 
The current curative treatment methods for HCC include liver transplantation, 
surgical resection and ablation [11]. Among these methods, liver 
transplantation is the most effective treatment, as it cures the patient from the 
tumour as well as the underlying cirrhotic liver, which might be pre-neoplastic 
and prone to secondary HCC development. However, the number of livers 
available for transplantation is limited, hence it is usually not the first choice 
of treatment for early stage HCC patients. Consequently, surgical resection 
becomes the next treatment of choice, especially for HCC patients without 
liver cirrhosis. Resection allows for the removal of the tumour from the liver. 
However, a sizable portion of the liver remnant is required to prevent liver 
failure [21]. The liver remnant may be cirrhotic in nature, which could 
promote the formation of de novo HCC. Ablation is an alternative treatment 
method if the size of the tumour is very small (less than 2 cm). It relies on the 
application of chemicals or temperature modification to induce necrosis of the 
tumour. The survival rates of Child-Pugh A patients undergoing ablation as 
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treatment are comparable to that of resection patients [22], making ablation an 
attractive treatment for early stage patients. However, ablation may not result 
in the complete removal of tumour, and its efficacy drops as the tumour size 
increases. Hence, the use of ablation in curative treatment is limited to patients 
with small and singular nodule. 
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1.2 HCC Recurrence  
1.2.1 Recurrence as the main cause of cancer-associated death after 
curative treatment 
Although the curative treatment methods have the potential to remove the 
primary tumour from the liver, the prognosis of HCC patients remains poor. 
The high recurrence rate of patients undertaking treatment with curative intent 
remains as the biggest challenge for management of HCC. 70% of patients 
suffer from recurrence after resective surgery [23, 24]. The rate of recurrence 
is lower in patients with liver transplantation, with less than 25% of liver 
transplantation patients suffering from recurrence. HCC recurrence is the main 
cause of death in HCC patients who undergo curative treatment [25]. Thus, 
understanding the molecular mechanisms of recurrence, and identifying 
patients with higher risk of recurrence would allow for a better management of 
the disease, thus improving the quality of life for the patients.  
1.2.2 Two main forms of HCC recurrence: intrahepatic metastasis and 
multicentric occurrence 
HCC recurrence can be generally classified into 2 types: intrahepatic 
metastasis and multicentric occurrence. These two types of recurrence forms 
have different risk factors and outcomes [25-29].  Intrahepatic metastasis 
arises from the undetected microscopic spread of the primary tumour. It is 
strongly associated with the formation of early recurrent tumours, which 
usually appear within 2 years after curative treatment. These tumours have 
high metastatic potential, are refractory to treatment, and result in a poor 5-
year survival rate as compared to patients suffering from late recurrence. 
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Clonality analyses had confirmed that the recurrent tumours originate from the 
primary tumour [30-32], but contained an increased number of genetic 
aberrations which conferred these recurrent tumours with more malignant 
traits that promoted its aggressiveness [33]. The risk factors for early 
recurrence are mostly tumour-related, of which venous invasion is the most 
common factor found among different studies.  
In contrast, multicentric occurrence results from the de novo formation of new 
tumours on the cirrhotic liver. These liver cells are usually dysplastic in nature 
and the continuous exposure to the inflammatory environment provides a 
“field” for cancer development. These tumours usually arise beyond 2 years 
after resection (late recurrence), and are of different clonal origin to the 
primary tumour. Hence, tumours arising from multicentric occurrence can be 
considered as new primary tumours, which are more responsive to treatment. 
In fact, late recurrence patients who undertook subsequent curative treatment 
for removal of these new tumours have a comparable survival rate to that of 
cirrhotic patients who have a high risk of developing primary HCC [34]. The 
risk factors for late recurrence are related to host factors, such as the degree of 
cirrhosis and the function of the remnant liver.               
1.2.3 Efforts to improve prognosis of HCC patients  
1.2.3.1 Building of models for prediction of HCC recurrence 
Early recurrence is the main reason for the poor prognosis of HCC patients 
who had received curative treatment. Current staging systems do not have 
sufficient power to predict the risk of cancer recurrence and survival in 
patients with early stage HCC. In an effort to improve on prognostication of 
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patients, different prediction models have been proposed. One such model is 
the building of nomograms based on the existing clinicopathological features 
observed in the patients. Different scores are given to variables that are 
associated with recurrence, and the sum of scores from the different variables 
will be used for accessing the risk of recurrence and patient survival. This 
scoring system is usually presented in the form of a nomogram, which allows 
for quick visualization and calculation of the scores using a ruler. Such 
nomograms have been proposed for prediction of early recurrence in patients 
receiving either surgical resection or liver transplantation as curative treatment 
[35-39]. Among these studies, vascular invasion is the only common variable 
included in all five nomograms. More importantly, these nomograms are built 
based on the information obtained from individual institutions. Hence, 
external validation of these nomograms is required to determine their 
applicability to HCC patients with different aetiological factors.  
1.2.3.2 Prevention of HCC recurrence in HBV and HCV-positive patients 
via adjuvant therapy  
Another viable strategy to prevent HCC recurrence would be to provide 
adjuvant therapy after curative treatment. This is applicable to HBV and HCV 
positive patients, in which high HBV viral loads [40-42] and persistent HCV 
viral infections are associated with higher recurrence rate after resection [43]. 
Hence, adjuvant therapies that help to reduce viral load in both HBV and HCV 
patients may prevent recurrence of these patients. Currently, nucleos(t)ide 
analogs are the standard treatment for controlling viral load in chronic HBV 
patients. Nucleos(t)ide analogs target the reverse transcriptase domain of HBV 
viral polymerase, which is required for synthesis of minus strand DNA during 
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HBV replication [44]. There are a total of 5 different nucleos(t)ide analogs 
currently available on the market, namely lamivudine, adefovir, entecavir, 
telbivudine, and tenofovir. Several retrospective studies have suggested the 
efficacy of nucleos(t)ide analog treatment in decreasing the recurrence rate 
and improving overall survival in HBV positive patients [45-47], even in 
patients with low HBV virus load [48]. These nucleos(t)ide analogs are highly 
tolerable and can be taken orally, hence they seem to be a viable option for 
preventing HBV-related  HCC recurrence. However, long term usage of 
nucleos(t)ide analogs may lead to generation of drug-resistant viral mutations 
[49, 50], which limits the efficacy of the drug, and might even promote HCC 
recurrence after multiple therapies [51].  
In the case of HCV, the standard treatment regimen for chronic HCV patient 
includes PEGylated-interferon plus ribavirin. A total of 6 different studies had 
looked into the effects of antiviral treatment on HCC recurrence [52-57]. The 
antiviral treatment was found to significantly reduce the rate of recurrence in 
most of these studies. However, this decrease is only linked to late recurrence. 
Hence, the efficacy of antiviral treatment, as well as HCV involvement in 




1.3 Proteomics for biomarker discovery and understanding of 
molecular mechanisms in HCC recurrence  
The prognosis of HCC patients remains poor due to the limited knowledge of 
the molecular mechanisms in promoting early recurrence, as well as the lack 
of a coherent system that can predict the risk of patients suffering from early 
recurrence. Proteomics provides a platform for large scale studies of the 
proteome, in which differentially expressed proteins can be used as prognostic 
biomarkers, in conjunction with other clinicopathological information, to 
stratify patients according to the risk of early recurrence. In addition, the 
changes in expression patterns of proteins allow for identification of pathways 
that are perturbed in the tumours of early recurrence patients. This allows for 
design of adjuvant therapies that may be administered to high risk patients for 
prevention of recurrence.  
1.3.1 Gel-based proteomics       
Gel-based proteomics involves the separation of proteins present in a complex 
sample by the polyacrylamide gel. 2-Dimensional Electrophoresis (2-DE) is 
the main workhorse of gel-based proteomics, in which proteins are first 
separated by their isoelectric point (pI) in isoelectric focusing (IEF), followed 
by molecular size via sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis (SDS-PAGE). The gels are subsequently stained to visualize 
the protein spots. Relative quantitation of protein spots is achieved by 
comparing the intensity of protein spots with matched pI and molecular size in 
different gels. To identify the protein(s) present in the gel spot, in-gel 
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trypsinization is performed and the tryptic peptides are subsequently subjected 
to mass spectrometry analysis for protein identification.   
Conventional 2-DE suffers from the lack of reproducibility of the spot patterns 
and intensities due to the high levels of inherent technical and systematic 
variability [58]. This led to the development of 2 Dimensional-Difference Gel 
Electrophoresis (2D-DIGE) [59]. In 2D-DIGE, the samples are first labelled 
with CyDyes, before the samples are combined and resolved by the 2-DE gels. 
Quantitative information can be obtained by measuring the fluorescent 
intensity of each protein spot. In addition, an internal standard can be added 
into each mixture for normalization and spot matching between different gels. 
These steps help to minimize technical variations arising from conventional 2-
DE experiments.  
Gel-based proteomics platform are useful for detection of post-translational 
modifications which would appear as a shift in the protein spot position. 
However, the resolution power of this technique is limited, and it is not 
particularly suited for separation of hydrophobic proteins such as membrane 
proteins.   
1.3.2 Liquid Chromatography (LC)-based proteomics   
LC-based proteomics involves the tryptic digestion of proteins into peptides, 
separation of peptides by LC, and followed by identification of peptides in the 
sample by tandem mass spectrometry (MS/MS) analysis. The identified 
peptides are matched to the proteins using bioinformatics. Various methods of 
protein quantitation are available, including labelling and label-free methods, 
which will be discussed below. 
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1.3.2.1 Metabolic labelling using Stable isotope labelling by amino acid in 
cell culture (SILAC) 
SILAC is a metabolic labelling method that involves the incorporation of 
stable isotopic labelled amino acids into the growing cells in vivo [60]. The 
cells are either grown in “heavy” media (containing 13C or 15N-labelled 
amino acids), or in “light” media (12C or 14N) for a few passages to ensure 
incorporation of these amino acids into the proteins. The lysates obtained from 
cells grown under 2 different conditions are mixed in a 1:1 ratio before 
trypsinization and LC-MS analysis. Quantitative information is obtained by 
comparing the intensity of the signals between the light and heavy peptides 
during MS analysis. A major drawback of SILAC is the requirement of amino 
acid incorporation into the cells, which cannot be achieved on tissue samples. 
However, this problem can be circumvented by the use of super-SILAC mix. 
In a proof of concept experiment by Geiger et al [61], proteomic analysis of 
breast cancer tissue was performed by combining the tissue lysate with a 
super-SILAC mix consisting of 5 different breast cancer cell lines that are 
SILAC-labelled. Quantitative information of the proteins in the tissue sample 
can be obtained by comparing with that of the SILAC-mix, which serves as an 
internal standard. This method can be easily expanded to other cancer types as 
long as cell lines that are representative of the cancer of interest are available.    
1.3.2.2 Chemical labelling methods in quantitative proteomics   
One of the commonly used chemical labelling methods in comparative 
proteomics is the utilization of isobaric tags for relative and absolute 
quantitation (iTRAQ) [62, 63]. The proteins extracted from the different 
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samples are trypsinized before labelling with the iTRAQ labels. These labels 
contain an amine reactive group, a balance group and a reporter mass (m/z 114 
to 117 for 4-plex, m/z 113 to 121, excluding 120 for 8-plex). The labels can 
bind to all tryptic peptides which contain free amino group at the N-termini, as 
well as the side chains of lysine. The different labels are isobaric, and thus 
have the same mass and chemical properties. Samples are mixed after 
labelling, and subsequently subjected to LC-MS/MS analysis. The precursor 
ions from the different samples will elute at the same time for MS analysis. 
Quantitative information is obtained in the MS/MS analysis, in which the 
reporter ions will be dissociated and their peak intensities can be compared for 
determination of relative abundance of proteins. This approach is robust and 
suitable for global expression profiling of different sample types, including 
tissue and cell lysate samples.  
Other chemical labelling methods include cleavable isotope coded affinity tags 
(cICAT) and Tandam Mass Tag (TMT) systems. The cICAT only labels the 
cysteine moiety, which might not be present in all proteins. Furthermore, 
cICAT only allows for a maximum of two samples to be labelled for a single 
analysis. The TMT system utilizes a similar labelling chemistry as iTRAQ. 
However, the 6-plex TMT can only label up to a maximum of 6 samples, 
while the 10-plex TMT requires modern mass spectrometers with sufficiently 
high resolution to distinguish reporter ion isotopologues with small differences 





1.3.2.3 Label-free approach in quantitative proteomics 
In a label-free proteomics approach, different samples are processed separately 
during LC-MS analysis. Spectrum counting is the most basic label-free 
quantitation method, which is based on the fact that an increased abundance of 
proteins will result in an increased number and frequency of peptides observed 
[65]. Relative quantitation of proteins can be obtained by comparing the 
number of spectrum counts between different samples. Spectrum counting 
methods can be used to estimate the relative abundance of the protein in a 
particular complex mixture by using exponentially modified protein 
abundance index [66]. 
Sequential Window Acquisition of all Theoretical fragment ion spectra Mass 
Spectrometry (SWATH-MS) is one of the recent label-free techniques that 
have emerged due to improvements in mass spectrometry technologies [67]. 
The acquisition method in SWATH-MS is data independent, in which a 
sequential mass window is utilized to acquire MS/MS information of all 
detectable peptides within that mass window. The information acquired can be 
used to generate a complete fragment ion map of the proteome. Quantitative 
information can be obtained from the extracted ion chromatogram of the 
peptides, similar to other targeted methods such as selected reaction 
monitoring (SRM). This approach is compatible with most sample types, and 
eliminates the need for labelling. Furthermore, this method can be used for 
validating results obtained from typical shotgun experiments, since their data 
acquisition method differs. Lastly, data generated from SWATH-MS 
demonstrates good reproducibility and consistency [68], which allows for 
comparison of data obtained from different runs given the conditions for LC-
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MS analysis remains similar. Thus, SWATH-MS technology provides a digital 
map of the proteome which can be mined retrospectively when new research 
questions arise.  
1.3.3 Proteomics studies in the identification of biomarkers for HCC 
recurrence   
The correlation found between tumour factors and risk of early recurrence led 
to proteomics studies on profiling of the primary tumour to decipher the 
molecular basis of recurrence and identify potential biomarkers that can 
predict the risk of early recurrence. There are a total of 9 studies that utilized 
proteomics for the identification of biomarkers for HCC recurrence. The 
details of these studies are summarized in Table 1-2. These existing studies 
can be broadly divided into two groups based on their study design. The first 
group of studies categorized the subjects according to the presence/absence of 
early recurrence within a stipulated time period for the discovery studies. Most 
of these studies selected only one of the proteins of interest for subsequent 
validation and functional studies, based on its discriminatory power or its 
possible biological relevance to HCC progression. The differentially regulated 
proteins that are identified in this category include mortalin [69], calpain small 
subunit 1 (CAPN4) [70], N-myc downstream-regulated gene 1 (NDRG1) [71], 
alpha-methylacyl-CoA racemase (AMACR) [72] and signal transducer and 
activator of transcription 1 (STAT1) [73]. Among these proteins, increased 
mortalin expression was observed in HCC cell lines with increasing metastatic 
potential, while the association between CAPN4 and NDRG1 expression and 
metastasis was demonstrated via cell-based assays. In all above-mentioned 
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studies, the correlation between target protein expression and recurrence was 
confirmed via western blot or immunohistochemistry.   
Some of the studies proposed the use of protein panels for prediction of 
recurrence risk based on the data derived from the discovery set, and the 
performance of these algorithms would be validated on a separate cohort of 
samples. This approach was used by Yookoo et al [74], who identified a 23-
proteins panel that can distinguish between early recurrence and non-
recurrence patients through 2D-DIGE. This panel managed to classify 16 out 
of 17 patients correctly in a validation cohort. However, the use of 2D-DIGE 
in validation requires skillful operators to minimize technical variations. 
Furthermore, the workflow for 2D-DIGE is laborious and difficult to translate 
to the clinic. Hence, this limits the applicability of the results obtained from 
this study.   
The second group of studies segregated the subjects based on pathological 
factors associated with HCC progression and prognosis. Orimo et al utilized 
tumour tissues with different histological differentiation status for discovery of 
proteins associated with HCC progression [75]. Increased microtubule-
associated protein RP/EB family member 1 (EB1) expression was found to be 
associated with poor differentiation of HCC cells, and was further determined 
to be an independent prognostic factor for recurrence after resection. 
Kanamori et al analysed a total of 4 HCC and non-HCC tissues from 2 
patients to identify proteins involved in HCC progression [76]. Talin-1 was 
found to be upregulated in HCC tissues, and immunohistochemical analysis 
linked high Talin-1 expression with poor differentiation, presence of portal 
vein invasion and intrahepatic metastasis.   
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Table 1-2: Proteomics studies for identification of HCC recurrence biomarkers  
Reference Sample type  Curative treatment Classification Aetiology  Discovery platform 
Candidate biomarkers 
(regulation) Validation  
Yokoo et 
al.,2007 [74] Tumour tissues  Surgical resection 
Recurrence within 6 months 
post surgery versus no 
















RP/EB family member 1 (↑) IHC 
Yi et al.,2008 
[69] 
Tumour, non-tumour 
and normal liver 
tissues 
Surgical resection 
Recurrence versus no 
recurrence within 1 year post 
surgery 
HBV  2DE, MALDI-TOF MS 
Stress-70 protein, 
mitochondrial (↑) IHC 
Bai et al.,2009 
[70] 
Tumour and non-
tumour tissues Liver transplantation  
Recurrence versus no 
recurrence within 3 years 
post transplantation  





al.,2011 [71] Tumour tissues Liver transplantation  
Recurrence versus no 
recurrence (time frame not 
stated) 






tumour tissues N.A 
Tumour versus adjacent non-
tumour HCV  2DLC-MS/MS Talin-1 (↑) IHC 
Tan et al.,2014 
[77] 
Paired tumour and 
non-tumour tissues Surgical resection 
Recurrence versus no 
recurrence within 2 years 






Heat shock 70 kDa protein 
1A/1B (↑) 
IHC, TMA  Argininosuccinate synthase (↓) 
UTP-glucose-1-phosphate 
uridylyltransferase (↓)                                   
Taoka et al.,2014 
[73] 
Tumour, non-tumour 
and normal liver 
tissues 
Surgical resection 
Recurrence within 2 years 
(ER), no recurrence after 2 
years (LR), adjacent non 
tumour tissue or normal liver 







Signal transducer and activator 
of transcription 1-alpha/beta (↑)  Western blot 
Huang et 
al.,2014 [72] Tumour tissues Surgical resection 
Recurrence within 6 months, 
recurrence between 6 to 12 
months and no recurrence 
within 2 years post surgery 
HBV iTRAQ-2DLC-MS/MS 
Alpha-methylacyl-CoA 
racemase (↓) IHC 
Protein S100-A12 (↓) 
The regulations of the candidate proteins are denoted by the arrows, where ↑ indicates an upregulation, and ↓ indicates a downregulation of 
protein expression in recurrence patients compared to non-recurrence. Abbreviations used: MALDI-TOF: matrix assisted laser desorption 




1.3.4 Limitations of current proteomics studies in predicting HCC 
recurrence 
The multitude of proteomics studies had identified numerous protein targets 
associated with recurrence of HCC. However, none of these targets are used 
clinically for prediction purposes. This could be attributed to the use of liver 
tissue samples obtained from patients with different aetiologies. Furthermore, 
the patients selected for the studies might have different HCC stages. An 
example would be the study by Yookoo et al, in which the early recurrence 
group consisted of late stage patients (stage III to IV) and the non-recurrence 
group patients consisted of mainly stage II patients [74]. Currently, prognostic 
information of the patients is obtained mainly through staging, thus the use of 
patients with different cancer stages might provide bias to the study. Lastly, 
the control samples used in different studies are not standardized. These 
control samples used include the tumour tissues of non-recurrence patients, 
adjacent non-tumour tissues and normal liver tissues, usually obtained from 
patients suffering from other diseases such as colorectal cancer. The lack of 
standardization of control samples used in the comparisons makes it difficult 
to correlate information obtained from different studies, thus hampering the 
process of identifying clinically usable biomarkers for predicting risk of 






1.4 Aims of study 
Early recurrence of HCC remains as a major obstacle in clinical management 
of HCC patients. This is reflected by the insufficiency of the staging systems 
to predict the risk of patients suffering from recurrence accurately, as well as 
availability of adjuvant treatment therapies that can help in preventing cancer 
recurrence. There has been little progress in the prognosis of HCC patients.  
Hence, it is imperative to look for new and better biomarkers that can predict 
the risk of early recurrence in HCC patients. In addition, it is preferable to 
identify proteins that can be potential targets for development of new therapies 
to prevent cancer recurrence.  
In order to achieve this, our lab has previously interrogated the liver tumour 
and adjacent non-tumour proteome of early recurrence HCC patients and non-
recurrence HCC patients using the 2D-DIGE approach [77]. The panel of 
tissue samples used was carefully selected such that only patients with stage I 
HCC at time of diagnosis were included in the study. Furthermore, the use of 
paired non-tumour tissue as the reference controls for variation of protein 
expression in different patients. The study identified and validated a total of 4 
proteins, namely heat shock 70 kDa protein 1 (HSP70), transketolase (TKT), 
UTP-glucose-1-phosphate uridylyltransferase (UGP2) and argininosuccinate 
synthase (ASS1) which were differentially expressed between the early 
recurrence and non-recurrence HCC patients.  In this study, we utilized an LC-
based quantitative proteomics approach in a bid to expand on the list of 
potential biomarkers that can be used for prediction of early HCC recurrence. 
Functional studies will be performed on a selected target to understand the 
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possible links between the expression of the protein target and HCC 
recurrence/progression.     
The aims of this project are summarized as follows:   
1. Identification of prognostic biomarkers for early HCC recurrence.  
The liver tissue proteome of early recurrence and non-recurrent stage I 
HCC patients were analyzed using iTRAQ labelling coupled with 2D-
LC MS/MS analysis. The expression patterns observed in the iTRAQ 
analysis were validated using SWATH-MS, and subsequently in a 
bigger patient cohort by western blot.   
2. Functional characterization of 2’-deoxynucleoside 5’-phosphate N-
hydrolase (DNPH1), a novel biomarker for HCC recurrence 
DNPH1 was found to be overexpressed in the tumours of early 
recurrence patients with a higher fold difference compared to the non-
recurrence patients in our discovery study. The role of DNPH1 
expression in HCC will be evaluated using cell line models. Hep3B 
with stable silencing of DNPH1 was established and the effects of 
DNPH1 knockdown on metastasis were evaluated via cell-based assays. 
iTRAQ analysis was performed to elucidate the molecular events that 
were affected by DNPH1 expression. The changes in protein 
expression in DNPH1 observed in this iTRAQ study will be used to 
provide explanations of the observed lowered metastatic potential of 
DNPH1 knockdown cells, as well as generate new hypothesis for 
involvement of DNPH1 in HCC progression.    
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Figure 1-3 illustrates the experimental workflow of the study in order to 














CHAPTER 2 MATERIALS AND METHODS 
2.1 HCC Tissue Samples 
2.1.1 Patient demographics and clinical information   
All liver tissue samples used in the iTRAQ analysis, SWATH-MS verification 
and western blot validation were previously used in the discovery sample set 
by Tan et al [77]. Briefly, the tumour and adjacent non-tumour liver tissues 
were obtained from HCC patients (n = 30) who had undergone curative 
surgery as part of treatment at Singapore General Hospital, Singapore. These 
tissues were stored in -80 oC prior to protein extraction. All HCC patients were 
stage I patients, had solitary tumours with no evidence of vascular invasion 
and metastatic spread of tumour to the lymph nodes or other organs during 
diagnosis and surgery. These patients were grouped according to their time of 
recurrence: (a) a non-recurrence (NR) group consisting of patients with 
disease-free survival of longer than 2 years after surgery; (b) An early 
recurrence (ER) group consisting of patients with HCC recurrence within 2 
years of surgery, which progressed to stage IV metastatic HCC. Patients in the 
ER group are numbered from 1 to 10, while patients in the NR group are 
numbered from 11 to 30. Tissue samples from 5 NR patients and 4 ER patients 
were used in the iTRAQ study and SWATH-MS analysis, while all available 
samples (n = 28; 19 from NR, 9 from ER) were used in western blot validation. 
Samples from patient number 1 (ER) and 26 (NR) were not included in the 
western blot validation due to misidentification of tissue type and lack of 
sufficient amounts of tissue lysates respectively. The demographic 
28 
 
characteristics and clinical data of these HCC patients are presented in Table 
2-1. 
Table 2-1: Demographic characteristics and clinical information of HCC 
patients (adopted from Tan et al. [77]) Liver tissue samples from 9 of these patients 
(5 from NR and 4 from ER) were used in the discovery phase and SWATH-MS 
verification. For western blot validation, samples from 28 patients (19 from NR, 9 
from ER) were used.  
Parameters  Non-Recurrence (NR) (n = 20) 
Early Recurrence 
(ER) (n = 10)  P 
Gender  
   Male  15 10  
Female  5 0  
Race     
Chinese  17 10  
Malay  2 0  
Others  1 0  
Age 64 (54.5, 69.5)a 63.5 (56.25, 72.25)a 0.65696b 
AFP levels (ng/mL) 9.85 (5.53, 48.38)a 145 (99.9, 479)a 0.01952b 
Tumour size (cm) 3.5 (2.88, 6.25)a 6.75 (3.88, 14.75)a 0.07949b 
Edmonson Grading     
1 (well-
differentiated) 3 6  
2 (moderately-
differentiated)  11 4  
3 (poorly 
differentiated)  6 0  
4 (undifferentiated)  0 0  
Cirrhosis     
Yes 12 7  
No  8 3  
Hepatitis Virus 
status     
Hepatitis B positive 12 6  
Hepatitis C positive 4 2  
no  4 2  
Recurrence-free 
time after surgery 
(months)  
69.5 (43.25, 84.25)a 13 (5.5, 16.25)a 8.39x10-6b 
 aData are represented as median (1st quartile, 3rd quartile). bStatistical analysis was 
performed using Mann-Whitney Test.  





2.1.2 Tissue lysate preparation 
The tissue lysates were prepared previously by Tan et al [77]. Briefly, 0.02 to 
0.05 mg of liver tissues were first washed with 1 x phosphate buffered saline 
(PBS), after which the tissues were placed in the grinding tube from the 
sample grinding kit (GE Healthcare Bio-Sciences, Uppsala, Sweden). 30 µl of 
lysis buffer consisting of 7 M urea, 2 M thiourea, 10 mM Tris, 4% 3-(3-
cholamidopropyl)dimethyammonio-1-propanesulfonate (CHAPS), 50 µg/ml 
RNase (Roche Diagnostic, Mannheim, Germany), 50 µg/ml DNase (Roche) 
and 1 x HALT protease inhibitor cocktail (Pierce, Rockford, IL, USA) was 
subsequently added to the liver tissue. The tubes and contents were snapped 
frozen by liquid nitrogen. The liver tissues were then grounded with the 
pestles during the process of thawing. The cycle of addition of lysis buffer, 
snap-freezing and grinding was repeated twice, with the final volume of lysis 
buffer added ranging from 100 to 150 µl. The samples were then centrifuged 
at 303475 g, 15 oC for 1 hour. The supernatant was retained and stored in -
80 oC until further use.        
2.1.3 2D Clean-Up of tissue lysates    
The tissue lysates were subjected to buffer exchange by precipitation using the 
2D Clean-Up kit (GE Healthcare) following the manufacturer’s instructions. 
The protein pellets were resuspended in 10 µl of TUTS buffer [78] containing 
25 mM Triethylammonium Bicarbonate (TEAB), 8M urea, 2% Triton X-100 
and 0.1% SDS. Protein concentrations of the tissue lysates were determined 
using the Coomassie Plus assay reagent kit (Pierce), with Bovine Serum 
30 
 
Albumin (BSA) as standard.  The lysates were stored in -80 oC until further 
use.    
2.2 Quantitative proteomics of liver tissue lysates using iTRAQ labelling 
technology 
2.2.1 Experimental setup  
For the discovery phase using iTRAQ-based quantitative proteomics, we 
employed the use of paired tumour and adjacent non-tumour tissue lysates 
from 9 patients (5 in NR and 4 in ER), which were randomly selected and 
checked for availability of tissue lysates. This resulted in a total of 18 different 
samples. However, each 8-plex iTRAQ kit can label up to a maximum of 8 
different samples in one experiment. Hence, in order to obtain quantitative 
information of all 18 samples, the samples were labelled separately in 3 
different batches, and each batch of labelled samples would be subjected to 
2D-LC MS/MS analysis separately, resulting in 3 independent iTRAQ 
“experiments”. The criteria for each iTRAQ experiment include: (i) the paired 
tumour and non-tumour tissue lysates for each patient must be present within 
the same iTRAQ experiment. (ii) Each iTRAQ experiment should consist of at 
least 1 patient sample from each group. (iii) Two pooled samples (pooled 
tumour and pooled non-tumour) were included in each iTRAQ experiment as 
representatives of the average proteome from the different samples used in the 
discovery phase. The experimental design for the iTRAQ analysis of tissue 
lysates is shown in Table 2-2. 
      
31 
 
Table 2-2: iTRAQ experimental design for HCC tissues. A total of 3 independent iTRAQ experiments were performed to profile 18 
different samples. The samples, labels and the iTRAQ experiments in which they were analysed in are stated in the table below.   
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2.2.2 Sample preparation and trypsin digestion  
50 µg of proteins from each tissue lysate sample was diluted to a final volume 
of 20 µl with TUTS buffer. The samples were first reduced with 1 µl of 50 
mM tris-(2-carboxyethyl)phosphine (TCEP) (SCIEX, MA, USA) for 1 hour at 
20 oC, followed by alkylation with 2 µl of 10 mM methyl methane-
thiosulfonate (MMTS) (SCIEX) for 10 min at 20 oC. After alkylation, the 
samples were then diluted 10-fold with 50 mM TEAB before digestion with 
10 µg of trypsin (SCIEX) for 16 hours at 37 oC.  
2.2.3 iTRAQ labelling and clean up 
After digestion, the samples were vacuum dried and reconstituted in 30 µl of 
500 mM TEAB for iTRAQ labelling. The iTRAQ labels were first 
reconstituted in 50 µl of isopropanol, then added to the respective samples and 
incubated at room temperature for 2 hours to allow labelling to take place. The 
pH of the samples was maintained at 8.0 for optimal labelling efficiency. After 
labelling, the samples were pooled together and passed through a strong cation 
exchange (SCX) cartridge as per manufacturer’s instructions (SCIEX). This 
step is required for removal of excess labels, undigested trypsin and other 
chemicals that might interfere with mass spectrometry analysis. The eluate 
from the SCX clean-up was diluted to a final volume of 5 ml with 
equilibration buffer (2% (v/v) acetonitrile (ACN) with 0.05% (v/v) formic acid 
(FA), then desalted by passing through a reverse phase Sep-pak C-18 cartridge 
(Millipore, MA, USA). Briefly, the C-18 cartridge was activated by passing 
through 10 ml of acetonitrile, then equilibrated with 10 ml of equilibration 
buffer. The diluted samples were then applied to the cartridge. The cartridge 
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was washed with 10 ml of equilibration buffer for removal of salts, before 
elution of peptides with 5 ml of elution buffer (80% ACN with 0.05% FA). 
The eluted samples were vacuum dried and reconstituted in 5% ACN with 
0.05% FA for 2D-LC separation.  
2.2.4 2D-LC separation  
Separation of the peptide mixture was first performed using a SCX column on 
the Ultimate LC system (Dionex-LC-packings, CA, USA). The mobile phases 
used were as follows: Mobile A: 5% ACN with 0.05% FA; Mobile B: 5% 
ACN, 500 mM NaCl with 0.05% FA. The dried peptide samples were first 
reconstituted in Mobile A, and subsequently 72 µg of the peptide mixture was 
injected into the Zorbax Bio-SCX II column (Agilent, CA, USA) by multiple 
injections via a micro-pickup loop. The flow rate was maintained at 10 µl/min 
and the peptides were separated using step gradients of mobile B as follows: 
0-10% for 10 min; 10-20% for 90 min; 20-60% for 20 min; 60-100% for 10 
min; hold at 100% for 5 min; 100-0% for 10 sec and holding at 0% for the last 
40 min. The eluted fractions were subsequently combined into 26 different 
fractions and then desalted with Sep-pak tC18 µElution plate (Waters 
Corporation, Milford, MA) using a vacuum manifold (Millipore). Briefly, the 
columns were first activated with 400 µl of ACN, then equilibrated twice with 
400 µl of equilibration buffer (2% ACN with 0.1% FA). The samples were 
added to the column after equilibration. The bound samples were then washed 
twice with equilibration buffer to remove salts present in the SCX elution 
buffer. The samples were then eluted with 200 µl of elution buffer (80% ACN 
with 0.05% FA) and dried by vacuum.  The dried fractions were reconstituted 
in 10 µl of 2% ACN with 0.1% FA for reverse phase (RP) separation.   
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For the RP separation, 5 µl of fraction was first trapped on a precolumn (200 
µm x 0.5 mm), then eluted into an analytical column (75 µm x 150 mm) for 
separation. Both the columns were packed with Reprosil-Pur C18-AQ 3 µm 
120 Å (Eksigent, CA, USA). The mobile phases used were as follows: Mobile 
A: 2% ACN with 0.1% FA; Mobile B: 98% ACN with 0.1% FA.  The flow 
rate was maintained at 300 nl/min and the peptides were separated using step 
gradients of mobile B as follows: 0-5% for 1 min, 5-12% for 2 min; 12-30% 
for 120 min and holding at 90% for the last 5 min. 
2.2.5 Tandem mass spectrometry analysis  
The tandem mass spectrometry analysis was performed on the 5600 
TripleTOF analyzer (SCIEX) in Information Dependent Mode. Precursor ions 
within the mass range of 400 to 1800 m/z were selected using accumulation 
time of 250 ms per spectrum. A maximum of 20 precursors from each MS 
spectrum were selected for MS/MS analysis with minimum accumulation time 
of 100 ms for each precursor and dynamic exclusion for 15 s. Tandem mass 
spectrometry was recorded in high sensitivity mode with rolling collision 
energy and iTRAQ reagent collision energy adjustment on.  
2.2.6 Protein and peptide identification  
The protein identification and relative iTRAQ quantitation were performed on 
ProteinPilot™ software 4.1 using the Paragon™ algorithm for peptide 
identification. The search parameters were as follows: (1) sample type: 
iTRAQ 8-plex (Peptide Labeled); (2) Cysteine Alkylation: MMTS; (3) 
Digestion: Trypsin; (4) Instrument: TripleTOF5600; (5) Special Factors: None; 
(6) Species: Homo sapiens; (7) ID focus: Biological modifications; (8) 
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Database: ipi.HUMAN.v3.87.fasta [79] (182888 proteins searched); (9) 
Search Effort: Thorough; (10) False Discovery Rate Analysis: Yes; (11) User 
Modified Parameter Files: Yes. For iTRAQ quantitation, the peptides for 
quantitation were selected by the ProGroup™ algorithm and the peak areas 
were extracted for relative quantitation. Auto bias correction was applied to 
correct for any variations that result from unequal mixing of samples. False 
discovery rate (FDR) determination was performed by searching the MS/MS 
data against a decoy database consisting of reverse sequences of all peptides in 
the IPI human database. Only proteins with unused score of above 1.3 (95% 
confidence interval) were selected for further analysis.   
2.2.7 Data analysis  
The tissue samples for Patient 1 in the early recurrence group were removed 
from subsequent analysis as the tumour tissue was discovered to be of non-
liver origin. A three-step filtering process was performed to identify proteins 
that are differentially expressed between the non-recurrence (NR) group and 
early recurrence (ER) group. Firstly, the IPI accession numbers of all proteins 
identified in the three independent runs were compared. Proteins with IPI 
accession numbers present in all 3 independent iTRAQ experiments were 
selected for further analysis. Subsequently, proteins that were differentially 
expressed between the paired tumour and non-tumour tissues of each patient 
(T/N ratio) were identified using a cutoff ratio. The cutoffs of >1.30 and 
<0.769 for upregulated and downregulated proteins were previously identified 
by Tan et al [80], which represented 2 standard deviations of all iTRAQ-
labelled peptides in a 6-protein mix. However, more stringent cutoffs of >1.40 
and <0.714 were applied in our study to match the stringency in identification 
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of differentially regulated proteins used in the 2D-DIGE experiment 
performed previously [77]. Only proteins that exhibit consistent regulation in 
at least 2 out of 3 patients and 3 out of 5 patients in the ER and NR groups, 
with no patients showing opposite regulation trends within the group (i.e. 
upregulated in some patients and downregulated in other patients) were 
considered. Lastly, the average T/N ratios of the proteins (calculated using 
geometric means) between the NR and ER groups must differ by at least 1.5 
fold to be considered as differentially expressed between the two groups. 
Principal Component Analysis was performed on MarkerView software 
version 1.2.1 (SCIEX) (Figure 3-2), and hierarchical clustering analysis was 
performed using Multiple Experiment Viewer [81] version 4.8.1 (Figure 3-3). 
Proteins that were differentially regulated between the two groups were 
annotated using Uniprot-GOA [82], and further verified by literature review of 
these proteins.  
2.3 SWATH-MS proteome profiling of tissue lysates for validation 
2.3.1 Sample preparation 
24 µg of tissue lysates were first diluted to a final volume of 20 µl with TUTS 
buffer. The samples were then reduced, alkylated and trypsinized as described 
previously in Section 2.2.2. The trypsinized samples were then subjected to 
SCX clean up (SCIEX) and desalted with Sep-pak tC18 µElution plate 
(Millipore). The samples were then vacuum dried and reconstituted in 24 µl of 
2% ACN with 0.1% FA. 
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2.3.2 SWATH-MS acquisition   
Each sample was analysed in triplicates during the SWATH-MS analysis. In 
each round of analysis, 4 µg of each sample was separated using the same 
reverse phase LC setup as mentioned in Section 2.2.4. The samples were then 
analyzed on the 5600 TripleTOF system in SWATH mode. In each cycle, a 50 
ms of TOF/MS survey scan was performed from 350 to 1250 Da in 36 
acquisition windows of 25 Da each and accumulation time of 80 ms. The time 
for each cycle of survey scan for all 36 windows was 3 s. The MS/MS 
acquisition was performed by scanning between 100 to 1800 Da, with 
collision energy of 35 V and spread of 15 V.  
2.3.3 Ion library generation and data analysis  
The ion library was generated by MS/MS analysis of a pooled sample 
consisting of equal amounts of peptides from all samples used in the SWATH-
MS analysis. 4 µg of pooled peptide sample was separated with identical LC 
parameters used in the SWATH-MS acquisition. The difference lies in the 
tandem mass spectrometry analysis, which was performed in Information 
Dependent Acquisition (IDA) mode for ion library generation. Precursor ions 
within the mass range of 350 to 1250 m/z were selected using accumulation 
time of 250 ms per spectrum. A maximum of 20 precursors from each MS 
spectrum were selected for MS/MS analysis with minimum accumulation time 
of 100 ms for each precursor and dynamic exclusion for 15 s. Tandem mass 
spectrometry was recorded in high sensitivity mode with rolling collision 
energy on.  
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Protein identification was performed using ProteinPilot 4.1 with the following 
search parameters: (1) Sample type: Identification; (2) Cysteine Alkylation: 
MMTS; (3) Digestion: Trypsin; (4) Instrument: TripleTOF5600; (5) Special 
Factors: None; (6) Species: Homo sapiens; (7) ID focus: Biological 
modifications; (8) Database: ipi.HUMAN.v3.87.fasta [79] (182888 proteins 
searched); (9) Search Effort: Thorough; (10) False Discovery Rate Analysis: 
Yes; (11) User Modified Parameter Files: No. Ion library matching and peak 
alignment was performed using the PeakView Software version 1.2 with the 
SWATH acquisition microapp plugin (SCIEX). Peak area calculation was 
performed using MarkerView Software version 1.2.1 (SCIEX). Quantitation 
was performed by comparing the peak area of paired tumour versus non-
tumour sample of individual patients, followed by averaging the T/N ratios 
from patients within each group.  
2.4 Cell culture and generation of stable knockdown cell lines  
2.4.1 HCC cell lines 
HepG2 and PLC/PRF/5 liver cancer cell lines were kindly provided by A/P 
Theresa Tan (Department of Biochemistry, NUS, Singapore). Hep3B cell line 
was provided by the Bioprocessing Technology Institute, Singapore.  
These three cell lines were maintained in Dulbecco’s Modified Eagles’ 
Medium (DMEM) (Sigma Aldrich, MO, USA) supplemented with 10% MEM 
non-essential amino acid (Gibco, Grand Island, USA), 10% sodium pyruvate 
(Sigma) and 10% FBS (Life Technologies, CA, USA) in a humidified 
incubator at 37 oC, 5% CO2.  The cell culture media for maintenance of stable 
knockdown Hep3B cell lines were further supplemented with 2.5 µg/ml of 
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puromycin (Sigma). The cells were passaged every 3-4 days upon reaching 80% 
to 90% confluency.  
2.4.2 Preparation of whole cell lysate  
HCC cells were grown to about 90% confluency before they were detached by 
trypsinization with 0.05% (w/v) trypsin-EDTA (Gibco). Neutralization of 
trypsin was performed by addition of DMEM containing 10% FBS. The 
detached cells were then centrifuged at 500 g, 15oC for 5 min before washing 
3 times with cold PBS. The harvested cells were then lysed in TUTS buffer 
with vortexing. The mixture was left to stand at room temperature for 15 min 
before centrifuging at 17,000 g, 15 oC for 1 hour to remove the cell debris. The 
supernatant was collected and protein quantitation was performed using 
Coomassie Plus assay reagent kit (Pierce), with BSA as standard. The cell 
lysates were stored in -80 oC until further use.      
2.4.3 DNPH1 knockdown constructs  
Silencing of DNPH1 expression was performed using a commercial DNPH1 
shRNA (29-mer) vector (pGFP-shDNPH1-V-RS; catalog no TG316927, 
Origene, MD, USA), which is selectable by puromycin in mammalian cells. 
The sequence of the shRNA used was 
GCCGTGGCCTTTAACAAGCGGATCCTGTG. pGFP-V-RS vector 
containing a 29-mer scrambled cassette sequence (catalog no TR30013, 
Origene) was used as the control. The sequence of the scrambled cassette was 
GCACTACCAGAGCTAACTCAGATAGTACT. The purpose of the control 
is to rule out any non-specific effects induced by expression of the vector.      
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2.4.4 Transfection of Hep3B cells and selection of stable cell lines 
2 x 105 Hep3B cells were seeded in 24-well plates and allowed to adhere 
overnight. 0.8 µg of either DNPH1 shRNA vector or scrambled control vector 
was first diluted with serum-free DMEM to a final volume of 50 µl per well. 2 
µl of Lipofectamine 2000 (Life Technologies) was added to 50 µl of serum-
free DMEM. The diluted Lipofectamine 2000 and plasmid DNA were mixed 
together in a 1:1 ratio and incubated for 20 minutes at room temperature. After 
incubation, 100 µl of the Lipofectamine 2000-plasmid DNA complex was 
added to each well and the cells were incubated at 37oC, 5% CO2 for 24 hours. 
The cells were subsequently trypsinized and seeded at 1:40 dilution in 6-well 
plates post transfection. Selection with puromycin (2.5 µg/ml) was then 
performed for 3 weeks. Within the 3 weeks, cells without stable gene 
integration died and those with successful gene integration grew as individual 
colonies. These colonies were then picked with brief trypsinization and 
cultured for 5 passages in 24 well plates. The colonies were checked for 
knockdown of DNPH1 expression by immunoblotting using anti-DNPH1 
antibodies (Abcam, Cambridge, UK). Hep3B cells with stable integration of 
DNPH1 silencing cassette were named as KD cells. Conversely, cells with 
stable integration of scrambled sequence cassette were named as SC cells. The 
SC cells would be used as the control for elucidating the effect of DNPH1 






2.5 Cell-based assays  
2.5.1 Wound healing assay  
Wound healing assays were performed using the ibidi culture insert (ibidi, 
Munich, Germany) in 6 well plates. Cells were first diluted to a concentration 
of 7 x 105 cells/ml in DMEM containing 10% FBS. 70 µl of cell suspension 
(4.9 x 104 cells) were then added to each chamber of the insert. The cells were 
incubated at 37 oC, 5% CO2 for 24 hours to allow the cells to adhere and form 
a confluent layer. At the start of the wound healing experiment, the insert was 
removed via sterile forceps. This resulted in a formation of a 500 µm gap 
between the cells seeded in the 2 chambers. The cells were then washed once 
with DMEM containing 1% FBS, 2.5 µg/ml puromycin before filling the wells 
with 2 ml of the above mentioned media. The closure of the gap was 
monitored at 0 hours and 24 hours, and the ability of the cells to close the gap 
was rated qualitatively by visual inspection. The experiment was repeated 3 
times.   
2.5.2  Transwell migration assay  
The transwell migration assay was performed using the 8.0 µm transwell 
migration inserts (Corning, NY, USA) in the 24-well plates. The undersides of 
the inserts were first coated with 300 µl of 10 µg/ml fibronectin (Sigma) for 
16 hours at 4 oC. After coating, the inserts were washed once with 1 x PBS.  
1.5 x 104 cells in 400 µl of DMEM containing 1% FBS were seeded into the 
insert. The outer chamber was filled with 500 µl of DMEM containing 10% 
FBS to create a chemo-attractant gradient. After 48 hours, cells that had not 
migrated were removed by gentle scrubbing with a cotton swab. The migrated 
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cells were then fixed in 4% (w/v) paraformaldehyde (Sigma) and stained with 
0.5% (w/v) crystal violet (Sigma) in 20% (v/v) methanol. For each insert, 5 
images are taken at random areas with 10x objective magnification. The 
number of migrated cells present in each image was tabulated using the 
ImageJ software [83]. The total number of cells in each insert was determined 
by summation of the number of cells in all 5 images. The total number of 
migrated KD cells was normalized to the control cell lines.  The experiments 
were repeated in triplicates and the normalized percentage change in migration 
from 3 independent experiments was plotted as mean ± SE. Statistical analysis 
was performed using Student’s t-test.   
2.5.3 Matrigel invasion assay 
The matrigel invasion assay was performed using the 8.0 µm BioCoat 
Matrigel Invasion inserts (Corning) in 24-well format. The inserts were first 
rehydrated with 500 µl of serum-free DMEM for 2 hours at 37 oC, 5% CO2. 
After rehydration, the inserts were washed once with serum-free DMEM 
before seeding 3.5 x 104 cells in 400 µl of DMEM containing 1% FBS. The 
outer chamber was filled with 500 µl of DMEM containing 10% FBS to create 
the chemo-attractant gradient, similar to that of the transwell migration assay. 
The cells were incubated for 72 hours for the cells to invade through the 
matrigel layer. To visualize and quantify cellular invasion, the cells were fixed 
and stained as described in Section 2.5.2. The experiments were repeated in 
triplicates and the normalized percentage change in invasion from 3 
independent experiments was plotted as mean ± SE. Statistical analysis was 
performed using Student’s t-test.      
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2.5.4 MTT cell proliferation assay 
1.5 x 104 cells were seeded in each well in a 24 well plate (Day 0). After 24, 
48 and 72 hours, 250 µl of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) dissolved in 1 x PBS were added to the 
wells and incubated for 2 hours at 37 oC, 5% CO2. After incubation, the 
contents were aspirated and the insoluble purple formazan was dissolved in 
500 µl of dimethyl sulfoxide (Sigma). Cell doubling was quantified by 
measuring the absorbance reading for each well at 570 nm, with the readings 
at 650 nm as background. The readings at each time point were then 
normalized to 24 hour.  All experiments were performed in 4 sets of wells and 
the experiment was repeated in triplicates. The results from the 3 independent 
experiments were plotted as mean fold change ± SE. Statistical analysis was 












2.6 iTRAQ analysis of KD and SC cells  
2.6.1 Experimental setup and sample preparation 
Quadruplicates of KD and SC cells from 4 different passages were harvested 
and lysed in the iTRAQ labelling buffer as mentioned in Section 2.4.2. These 
4 different passages represent 4 biological replicates for analysis. The samples 
and the respective iTRAQ labels are shown in Table 2-3. 50 µg of each sample 
were subjected to reduction, cysteine blocking, trypsin digestion, iTRAQ 
labelling and SCX clean up as stated previously in Sections 2.2.2 and 2.2.3.   
    
Table 2-3: Experimental setup for iTRAQ analysis of KD and SC cells 


















2.6.2 Reverse Phase-LC separation 
2 µg of iTRAQ labelled peptides was first trapped on nano cHiPLC trap 
column (200 µm x 0.5 mm), then eluted into nano cHiPLC analytical column 
(75 µm x 150 mm) for separation. Both the columns were packed with 
ChromXP C18-CL 3 µm 120 Å (Eksigent). The mobile phases used were as 
follows: Mobile A: 2% ACN with 0.1% FA; Mobile B: 98% ACN with 0.1% 
FA.  The flow rate was maintained at 300 nl/min and the peptides were 
separated using step gradients of mobile B as follows: 0-5% for 1 min, 5-10% 
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for 9 min; 10-25% for 70 min; 25-40% for 15min; 40-90% for 10 min; holding 
at 90% for 15 min and equilibration at 5% for 15 min.    
2.6.3 Tandem mass spectrometry analysis  
The tandem mass spectrometry analysis was performed on the 6600 
TripleTOF analyzer (SCIEX) in Information Dependent Mode. Precursor ions 
within the mass range of 350 to 1800 m/z were selected using accumulation 
time of 250 ms per spectrum. A maximum of 30 precursors from each MS 
spectrum were selected for MS/MS analysis with accumulation time of 100 ms 
for each precursor based on precursor intensity (>125 counts), charge state (2-
5) and dynamic exclusion for 20 s. Tandem mass spectrometry was recorded 
in high sensitivity mode with rolling collision energy and iTRAQ reagent 
collision energy adjustment on.  
2.6.4 Protein and peptide identification  
The protein identification and relative iTRAQ quantitation were performed on 
ProteinPilot™ software v4.5 and searched against the Swiss-Prot Human 
database.  Auto bias correction was applied, and FDR determination was 
performed by utilizing a decoy database consisting of reverse sequences from 
the Swiss-Prot Human database. Proteins with unused score of above 1.3 (95% 
confidence) were selected for further analysis. 
2.6.5 Data analysis   
Differentially expressed proteins between KD and SC were determined 
following these 3 criteria: (i) the iTRAQ ratio of KD to SC for the proteins 
must be > 1.30 or < 0.769 to be considered as upregulated and downregulated 
46 
 
in KD cells respectively (as previously determined by Tan et al [80]) ; (ii) the 
differential regulation must be observed in at least 12 out of the 16 
comparisons across the 4 biological replicates and (iii) no opposite regulation 
was observed across the 16 comparisons. The protein ratios of KD to SC were 
presented as the average of the 16 comparisons in Table 3-3. Proteins that 
were differentially regulated between the two groups were annotated using 
Uniprot-GOA. 
2.7 Western blotting  
10 µg of protein lysates were first separated in 12.5% gels, and transferred to 
PVDF membrane (Bio-Rad laboratories) by Trans-Blot transfer cell in Towbin 
buffer with SDS (0.025M Tris, 0.192M glycine, 0.1% SDS, 20% methanol) 
for 30 minutes at 100V. The membranes were then blocked in 5% milk/TBST 
at room temperature for 1 hour and incubated with the primary antibodies. All 
primary antibodies were diluted in 1% milk/TBST and incubated for 2 hours at 
room temperature, except for anti-TXN, which was incubated overnight at 
4 oC. The blots were then washed 3 x 5 min with TBST before incubation with 
the appropriate secondary antibodies that were diluted in 1% milk/TBST for 1 
hour at room temperature. The blots were then washed 3 x 5 min with TBST 
before visualization.   For visualization of immunoreactive bands, Supersignal 
West Dura Extended Duration substrate (Pierce) was added to the blot, and the 
immunnoreactive bands were visualized and captured using the ChemiDoc 
MP System (Bio-Rad). Densitometry analysis of the immunoreactive bands 
was performed on Image Lab Software version 4.1 (Bio-Rad). After 
immunoblotting, the membranes were stained using Colloidal Silver solution 
(2% (w/v) sodium citrate, 0.8% (w/v) iron (II) sulphate and 0.2% (w/v) silver 
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nitrate) for visualization of total protein profile. The lists of primary and 
secondary antibodies used are shown in Tables 2-4 and 2-5 respectively. 
Table 2-4: List of primary antibodies used  
Manufacturer  Product code Target  Host  Dilution  
Abcam  
ab131252 DNPH1  Rabbit monoclonal  1:10,000  
ab108600 HSP10  Rabbit monoclonal  1:20,000 
ab7754 KRT19 Mouse monoclonal 1:10,000 
ab92547 VIM  Rabbit monoclonal  1:5,000 
ab80588  NQO1 Rabbit monoclonal  1:25,000 
ab185329 TXN Rabbit polyclonal  1:1,000 
ab6276 Actin Mouse monoclonal 1:10,000 
Santa Cruz sc-25778  GAPDH Rabbit polyclonal  1:3,000 
 
 
Table 2-5: List of secondary antibodies used  
Manufacturer  Product code Antibody Dilution  
Santa Cruz sc-2004 Goat anti-rabbit 1:10,000 










































CHAPTER 3 RESULTS  
3.1 iTRAQ and 2D-LC MS/MS analysis of liver tissue proteome  
We employed a combination of iTRAQ (8-plex) labelling and two-
dimensional liquid chromatography coupled with mass spectrometry to 
interrogate the relative expression levels of proteins in tumour and adjacent 
non-tumour tissue samples from 9 stage I HCC patients. A total of 3 
independent sets of iTRAQ experiments were performed to obtain quantitative 
information of proteins in all 18 samples. An average of 2335 proteins was 
identified in each iTRAQ experiment by two or more peptides with unused 
score of more than 1.3, among which 1191 proteins were commonly identified 
in all three iTRAQ experiments. These 1191 proteins were subjected to further 
analysis. 
 
Figure 3-1: Venn diagram depicting overlap between 3 iTRAQ experiments. 
An average of 2335 proteins was identified in each experiment, of which 1191 
proteins were common in all 3 experiments. These commonly identified proteins 




3.2.1 Differentially expressed proteins found in Early Recurrence versus 
Non-Recurrence HCC tissues 
The tissue samples from one of the patients in the ER group were removed 
from subsequent analysis as it was discovered that the tissue samples was not 
of liver origin after tracking the source of the tissues through the patient 
database. Consequently, only tissue samples from 3 patients in the ER group 
and 5 patients in NR group were considered for determination of differentially 
expressed proteins between the two groups. The process involved the 
identification of proteins that were consistently regulated within each patient 
group, before applying a cutoff of > 1.5 fold difference between the average 
T/N ratios from each group to identify proteins that were differentially 
expressed between the two groups (detailed explanation in Section 2.4.2.5). Of 
the 1191 proteins commonly identified in all samples, 52 of them were found 
to be differentially regulated between the ER and NR group. The list of 








Table 3-1: 52 proteins that are differentially expressed in tumours of NR 
and ER patients identified by iTRAQ. The T/N ratio for each protein was obtained 
for individual patients, before the average T/N ratios were compared between the two 





Non-Recurrence Early Recurrence 
Average 
T/N ratio G.S.D  
Average 
T/N ratio G.S.D  
Q13268 DHRS2 dehydrogenase/reductase SDR family member 2, mitochondrial 0.994 1.225 2.984 3.460 
Q969Z0 TBRG4 Protein TBRG4 1.406 1.532 2.759 1.063 
Q13501 SQSTM1 Sequestosome-1 1.179 1.463 2.675 3.135 
P56470 LGALS4 Galectin-4 0.744 1.608 2.596 1.537 
P0DMV8, 
P0DMV9 
HSPA1B;HSPA1A Heat shock 70 kDa 
protein 1A/1B 1.328 1.354 2.593 1.216 
Q13885 TUBB2A Tubulin beta-2A chain 1.445 1.479 2.448 1.257 
P61604 HSPE1 10 kDa heat shock protein, mitochondrial 1.492 1.404 2.241 1.486 
Q99541 PLIN2 Perilipin-2 1.372 1.413 2.152 1.368 
O14980 XPO1 Exportin-1 1.346 1.275 2.075 1.557 
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 1.159 1.379 1.744 1.189 
Q9NTI5 PDS5B Sister chromatid cohesion protein PDS5 homolog B 0.964 1.357 1.738 1.239 
O15382 BCAT2 Branched-chain-amino-acid aminotransferase, mitochondrial 0.873 1.532 1.601 1.508 
O43598 DNPH1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 0.970 1.228 1.600 1.811 
Q13451 FKBP5 Peptidyl-prolyl cis-trans isomerase FKBP5 0.886 1.319 1.597 1.171 
P54577 YARS Tyrosyl-tRNA ligase, cytoplasmic 0.904 1.180 1.467 1.201 
Q9H9B4 SFXN1 Sideroflexin-1 0.762 1.572 1.394 1.079 
P13073 COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 0.711 1.153 1.196 1.350 
P11182 
DBT Lipoamide acyltransferase 
component of branched-chain alpha-keto 
acid dehydrogenase complex, 
mitochondrial 
0.636 1.410 1.098 1.437 
P01019 AGT Angiotensinogen 1.633 1.779 1.088 1.203 
P53396 ACLY ATP-citrate synthase 2.026 1.617 1.028 1.347 
P23786 CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial 0.646 1.263 1.015 1.163 
O00483 NDUFA4 Cytochrome c oxidase subunit NDUFA4 0.654 1.463 1.009 1.412 
Q13907 IDI1 Isopentenyl-diphosphate Delta-isomerase 1 1.934 2.510 0.859 1.053 
P30613 PKLR Pyruvate kinase 1.329 1.729 0.848 1.143 
PTGR1 PTGR1 Prostaglandin reductase 1 0.442 2.072 0.728 1.511 
P05181 CYP2E1 Cytochrome P450 2E1 0.415 1.731 0.714 1.482 
 P48147 PREP Prolyl endopeptidase 1.127 1.313 0.702 1.405 
O43704 SULT1B1 Sulfotransferase family cytosolic 1B member 1 0.463 1.877 0.697 1.377 
P15144 ANPEP Aminopeptidase N 1.041 1.302 0.673 1.129 








Non-Recurrence Early Recurrence 
Average 
T/N ratio G.S.D  
Average 
T/N ratio G.S.D  
P46060 RANGAP1 Ran GTPase-activating protein 1 0.995 1.183 0.586 1.193 
O94905 ERLIN2 Erlin-2 0.869 1.453 0.559 1.330 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 1.135 1.820 0.534 1.293 
P30038 ALDH4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 0.790 1.456 0.514 1.358 
Q5SRE7 PHYHD1 Phytanoyl-CoA dioxygenase domain-containing protein 1 1.047 1.082 0.486 1.398 
P61313 RPL15 60S ribosomal protein L15 0.895 1.459 0.483 2.155 
Q96KP4 CNDP2 Cytosolic non-specific dipeptidase 0.758 1.252 0.480 1.264 
A6NDB9 PALM3 Paralemmin-3 0.806 1.399 0.469 1.783 
P50453 SERPINB9 Serpin B9 0.759 1.181 0.462 1.010 
Q02252 ALDH6A1 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 0.731 1.655 0.459 2.231 
Q08AH3 ACSM2A Acyl-coenzyme A synthetase ACSM2A, mitochondrial 0.800 1.518 0.454 1.918 
P00738 HP Haptoglobin 0.693 1.478 0.451 1.333 
Q08477 CYP4F3 Docosahexaenoic acid omega-hydroxylase CYP4F3 0.848 1.456 0.419 1.914 
Q96IU4 ABHD14B Alpha/beta hydrolase domain-containing protein 14B 0.640 1.747 0.415 1.438 
Q8WYK0 ACOT12 Acyl-coenzyme A thioesterase 12 0.592 1.539 0.379 1.441 
Q02928 CYP4A11 Cytochrome P450 4A11 0.590 1.827 0.377 1.459 
P17516 AKR1C4 Aldo-keto reductase family 1 member C4 0.606 1.497 0.344 3.315 
Q14117 DPYS Dihydropyrimidinase 0.665 1.826 0.317 3.087 
Q6PAU8 SLC2A2 SLC2A2 protein 0.630 1.682 0.313 2.062 
P05089 ARG1 Arginase-1 0.681 1.390 0.311 2.409 
O95154 AKR7A3 Aflatoxin B1 aldehyde reductase member 3 0.414 2.845 0.261 2.053 









3.2.2 Utility of the 52 proteins in distinguishing ER and NR patients   
In order to confirm the efficacy of the cutoff criteria used in selecting proteins 
that can segregate the two groups of patients, the list of 52 proteins were 
subjected to unsupervised Principle Component Analysis and hierarchical 
clustering. This protein list managed to successfully categorize the patients 
into 2 distinct groups based on their recurrence status in both analyses (Figures 
3-2 and 3-3). This validates the credibility of the criteria that was set for 




















Figure 3-2: Unsupervised Principle Component Analysis of the differentially 
regulated proteins. The T/N ratios of the 52 differentially regulated proteins in 
individual patients were used for the PCA analysis. Patient numbers 5, 7 and 9 belong 
to ER group and patient numbers 23, 25, 28, 29 and 30 belong to NR group.  The 
patients in the ER group are clearly separated from the patients in the NR group by 











Figure 3-3: Hierarchical clustering analysis of differentially regulated 
proteins.   The T/N ratios of the 52 proteins for individual patients were used for 
hierarchical clustering analysis and the dendrogram showed that the 52 proteins list 







3.2.3 Functional annotation of differentially regulated proteins between 
tumours of ER patients and NR patients 
Functional annotation of the differentially expressed proteins were performed 
using Uniprot-GOA [82], with further confirmation of the annotation of the 
proteins by literature review. As shown in Figure 3-4, majority of the 
differentially regulated proteins are involved in metabolism.  Dysregulation of 
metabolic enzymes is common in HCC due to a loss of liver function during 
cellular dedifferentiation and tumourigenesis. Additionally, differential 
regulations of cellular stress mediators, such as the upregulation of heat shock 
proteins, promote survival of tumour cells in a harsh inflammation-based 
background. In depth discussion of differentially expressed proteins involved 
in metabolism and regulation of cellular stress will be performed in Section 
4.3.    
 
Figure 3-4: Functional annotation of differentially expressed proteins in 
tumours of ER and NR patients. The differentially expressed proteins in the 
tumours of ER and NR patients were annotated using information from Uniprot-GOA 
[82], and confirmed by literature.  
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3.3 Validation of the iTRAQ results with SWATH-MS  
SWATH-MS analysis was performed on the tissue lysates of the same 8 
patients used in the discovery phase to validate the protein regulations 
observed in iTRAQ analysis. A total of 11 proteins demonstrated similar 
correlation of T/N results in both SWATH-MS and iTRAQ analysis. The list 
of proteins that were validated via SWATH-MS analysis is shown in Table 3-2. 
The possible reasons for differences in protein regulations are discussed in 
Section 4.1.4.     
Table 3-2: SWATH-MS validation of iTRAQ results. The table shows the list 
of differentially expressed proteins identified in iTRAQ that exhibited similar 
expression patterns in SWATH-MS analysis. The values obtained from both iTRAQ 
and SWATH-MS analysis are reported as geometric mean (geometric standard 
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3.4 Validation by Western blotting 
The iTRAQ and SWATH-MS analysis were applied to a small number of 
patient samples (n = 8) and thus may be subjected to sample bias. Hence, 
validation of protein expression was performed on a larger cohort of patient 
samples to confirm the differences in protein expression between ER and NR 
groups as observed in iTRAQ and SWATH-MS analyses. Western blot 
analysis was performed on the paired liver tissue lysates of 28 patients (9 ER, 
19 NR), and densitometry readings of immuno-reactive bands were obtained 
to determine the T/N ratios of target protein in the individual patients. The 
regulations of DNPH1 and HSP10 were successfully validated by western 
blotting. DNPH1 and HSP10 were significantly upregulated in the tumours of 
ER than that of NR group (p = 0.0275 and p = 0.007 respectively, Mann-
Whitney Test). The western blot images and box plots for densitometry 
analysis for DNPH1 and HSP10 are shown in Figure 3-5.   
Actin was also immunoblotted as a housekeeping gene that is commonly used 
as a loading control to evaluate the equal loading of proteins across samples 
(Appendix I). However, actin was observed to be regulated within patient 
samples and varied greatly across different patient samples. The 
appropriateness of common housekeeping genes as loading controls in HCC 
and western blotting had been previously discussed [84, 85], and total protein 
staining may be a more appropriate way to evaluate the protein loading [86]. 
Hence, silver colloidal stains of PVDF membranes were used to confirm the 






Figure 3-5: Validation of DNPH1 and HSP10 expression by western blotting. 
Increased expression of (A) DNPH1 and (B) HSP10 expression in the tumour of early 
recurrence patients  were validated using western blot in a larger cohort of patient 
samples (NR = 19, ER = 9). The immuno-reactive bands of paired non-tumour (N) 
and tumour (T) samples, together with the patient numbers, were shown in (A) and 
(B). The immunoreactive bands were quantitated using Image Lab software (Bio-Rad) 
and the T/N ratios for (C) DNPH1 and (D) HSP10 were represented using box plots. 
Statistical analyses were performed using Mann-Whitney Test.  Equal loading was 






3.5 DNPH1 expression in HCC cell lines 
The protein expression of DNPH1 was determined in a panel of 3 HCC cell 
lines (HepG2, Hep3B and PLC/PRF/5) via western blot (Figure 3-6). These 
three cell lines are well-differentiated cell lines that are commonly used for 
understanding the biology of HCC development in the literature. Among these 
cell lines, Hep3B has the highest expression of DNPH1. In addition, Hep3B 
contains an integrated hepatitis B virus genome, which is reflective of the 
main aetiological factor of HCC in Singapore. The cell line is also amenable to 
transfection. Thus, Hep3B was chosen for elucidation of DNPH1 function in 




Figure 3-6: DNPH1 protein levels in 3 different HCC cell lines. Western 
blotting showed that Hep3B cells have the highest DNPH1 protein level among the 3 
different cell lines. Actin and GAPDH were probed as loading controls. Equal 
loading was further confirmed by colloidal silver staining of the membrane 








3.6 Stable DNPH1 knockdown in Hep3B cells  
Silencing of DNPH1 in Hep3B cells was performed using commercial shRNA 
vectors. The cells were first transfected for a period of 2 days before selection 
of individual colonies that survived in selection media containing 2.5µg/ml 
puromycin. Individual colonies were picked and grown in selection media for 
5 passages to confirm stable integration of the silencing cassette. The 
morphology of the stable DNPH1 knockdown (KD) and scrambled control 
(SC) Hep3B cells are shown in Figure 3-7. There are no distinct differences in 




Figure 3-7: Morphology of DNPH1 scrambled control and knockdown cells. 
Cells were maintained at 1.25µg/ml puromycin in DMEM media and allowed to grow 







Western blot analysis was performed on KD and SC cells to confirm the 
protein expression levels of DNPH1 in these cells. This pair of cell lines 




Figure 3-8: Western blot analysis of DNPH1 levels in knockdown and 
scrambled control cells. Immunoblotting showed lower DNPH1 protein levels in 
knockdown cell line, suggesting successful silencing of DNPH1 expression. Actin 




3.7 Effects of DNPH1 knockdown on Hep3B migration 
The effect of suppression of DNPH1 level on Hep3B migration was assessed 
by two in vitro assays. Qualitative assessments of cell migration were 
performed using a wound healing assay. As shown in Figure 3-9, KD cells 
exhibited slower wound closure as compared to SC cells within the 24 hour 
experimental time period. 
 
 
Figure 3-9: DNPH1 knockdown results in slower wound healing. Wound 
healing assay was performed over a period of 24 hours. The experiment was repeated 
3 times and representative photos are shown Figure 3-9.  The gap between the SC 
cells (A and B)  is smaller than that of KD (C and D) after 24 hours, suggesting that 






To further confirm the effect of DNPH1 expression on cell migration, a 
quantitative assessment was performed using transwell migration assay. Stable 
DNPH1 knockdown in Hep3B significantly decreased the number of migrated 
cells (p < 0.05) as compared to scrambled control (Figure 3-10). These results 
implicate the involvement of DNPH1 in the migration capability of HCC cells.        
Figure 3-10: DNPH1 knockdown decreases cell migration. (A-B): 
Representative pictures of migrated SC and KD cells. Cells were visualized by 
staining with crystal violet. (C): Graphical representation of transwell migration 
results. The experiment was repeated 3 times and the normalized migration was 
plotted as mean ± SE. Statistical analysis was performed using Student’s t-test. 
DNPH1 knockdown resulted in a significant reduction in transwell migration of 





3.8 Effects of DNPH1 knockdown on Hep3B invasion   
The effects of DNPH1 knockdown in HCC cells invasion in vitro was also 
determined using a Matrigel Invasion assay. Knockdown of DNPH1 resulted 
in a significant decrease in number of invaded cells (Figure 3-11). Hence, 
DNPH1 expression may modulate the invasive behaviour of HCC cells.   
Figure 3-11: DNPH1 knockdown decreases cell invasion. (A-B): Representative 
pictures of invaded SC and KD cells. Cells were visualized by staining with crystal 
violet. (C): Graphical representation of matrigel invasion results. The experiment was 
repeated 3 times and the normalized invasion was presented as mean ± SE. Statistical 
analysis was performed using Student’s t-test. DNPH1 knockdown significantly 








3.9 Effects of DNPH1 knockdown on Hep3B proliferation rate 
DNPH1 has been implicated as a growth-related oncogene, hence the effects 
of DNPH1 knockdown on HCC cells were studied via the MTT proliferation 
assay. The growth of cells was measured for a total of 3 days, and surprisingly, 
there were no significant differences in the doubling rates of KD and SC cells. 
The results of the MTT assay are shown in Figure 3-12.  
 
 
Figure 3-12: MTT proliferation assay of SC and KD cells. The MTT 
proliferation assay was performed in quadruplicate, and the fold change was plotted 
as mean ± SE (n=3). Statistical analysis was performed using Student’s t-test. 
DNPH1 silencing does not alter the doubling rate of Hep3B cells within a 3 day 







3.10 iTRAQ analysis of DNPH1 knockdown Hep3B cells   
To elucidate the molecular changes elicited by DNPH1 knockdown, we 
employed the use of iTRAQ to study the quantitative changes in the proteome 
of KD and SC cells. A total of 1850 proteins were identified using an unused 
score cutoff of 1.3, of which 56 proteins showed consistent differential 
expression between KD and SC cells. Among the 56 proteins, 24 proteins 
were found to be overexpressed, and 32 proteins were downregulated in KD 
cells respectively. The list of differentially expressed proteins is shown in 

















(95%)  Protein name 
Average KD:SC 
ratio 
Q9Y399 5.7 1 MRPS2 28S ribosomal protein S2, mitochondrial  25.943 
Q04828 51.1 12 AKR1C1 Aldo-keto reductase family 1 member C1 3.931 
P25815 51.6 3 S100P Protein S100-P  3.122 
Q9H4M9 12.7 3 EHD1 EH domain-containing protein 1  2.340 
P07148 80.3 8 FABP1 Fatty acid-binding protein, liver  2.287 
A4D1E9 10.1 1 GTPBP10 GTP-binding protein 10  2.225 
P15559 45.3 7 NQO1 NAD(P)H dehydrogenase [quinone] 1  2.168 
O95490 6.9 1 LPHN2  Latrophilin-2  1.800 
O76031 10 1 CLPX ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial  1.738 
P07108 62.1 3 DBI Acyl-CoA-binding protein  1.696 
O60701 77.5 29 UGDH UDP-glucose 6-dehydrogenase 1.618 
P50226 18 1 SULT1A2 Sulfotransferase 1A2 1.612 
Q6UW78 32.3 3 UQCC3 Ubiquinol-cytochrome-c reductase complex assembly factor 3  1.585 
Q14914 29.2 2 PTGR1 Prostaglandin reductase 1  1.533 
P14618 73.5 30 PKM Pyruvate kinase PKM 1.523 
Q9BY49 60.4 11 PECR Peroxisomal trans-2-enoyl-CoA reductase  1.510 
O75874 57.7 16 IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic  1.505 
Q9Y2R0 17.9 1 COA3 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial  1.458 
Q96C01 48.6 2 FAM136A Protein FAM136A  1.451 















(95%)  Protein name 
Average KD:SC 
ratio 
P10599 53.3 4 TXN Thioredoxin  1.420 
Q9H6R3 41.6 10 ACSS3 Acyl-CoA synthetase short-chain family member 3, mitochondrial  1.402 
P47755 48.3 6 CAPZA2 F-actin-capping protein subunit alpha-2  1.394 
P29401 48 13 TKT Transketolase 1.370 
Q9H1E3 16.9 3 NUCKS1 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 0.746 
Q9BRQ8 14.2 2 AIFM2 Apoptosis-inducing factor 2  0.740 
Q7L8L6 9.2 1 FASTKD5 FAST kinase domain-containing protein 5 0.706 
O43169 33.6 2 CYB5B Cytochrome b5 type B 0.701 
P28370 14.4 6 SMARCA1 Probable global transcription activator SNF2L1  0.699 
P58107 10 21.9 EPPK1 Epiplakin  0.699 
P01130 2 1 LDLR Low-density lipoprotein receptor  0.690 
Q9UHB6 9.4 1 LIMA1 LIM domain and actin-binding protein 1 0.688 
Q6P587 13.4 1 FAHD1 Acylpyruvase FAHD1, mitochondrial 0.683 
Q9UFN0 9.3 1 NIPSNAP3A Protein NipSnap homolog 3A  0.682 
P48449 30.2 11 LSS Lanosterol synthase  0.681 
Q9H3P2 11 1 NELFA Negative elongation factor A  0.671 
Q99757 42.2 4 TXN2 Thioredoxin, mitochondrial  0.659 
Q03252 36.7 13 LMNB2 Lamin-B2  0.644 
Q14254 27.1 6 FLOT2 Flotillin-2  0.630 
Q9Y3U8 14.3 1 RPL36 60S ribosomal protein L36  0.627 
Q8IV08 19.4 6 PLD3 Phospholipase D3  0.625 
P53999 29.9 3 SUB1 Activated RNA polymerase II transcriptional coactivator p15  0.624 
P21964 36.9 6 COMT Catechol O-methyltransferase 0.622 
Q14011 43 2 CIRBP Cold-inducible RNA-binding protein  0.613 










(95%)  Protein name 
Average KD:SC 
ratio 
Q8N183 29 1 NDUFAF2 Mimitin, mitochondrial  0.544 
Q99856 16.9 2 ARID3A AT-rich interactive domain-containing protein 3A 0.541 
Q99943 9.5 1 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 0.539 
Q13740 23.2 7 ALCAM CD166 antigen 0.536 
Q6PKG0 6.8 1 LARP1 La-related protein 1  0.530 
P08727 73 19 KRT19 Keratin, type I cytoskeletal 19  0.524 
Q9H490 3.9 1 PIGU Phosphatidylinositol glycan anchor biosynthesis class U protein 0.493 
O00764 16.4 2 PDXK Pyridoxal kinase 0.489 
P55327 15.6 1 TPD52 Tumor protein D52  0.414 
P10301 11.8 2 RRAS Ras-related protein R-Ras  0.379 
P08670 57.5 23 VIM Vimentin  0.340 
The functional relevance of proteins that are shaded will be discussed in Sections 4.4.2.1 to 4.4.2.4.    
% coverage: the percentage of matching amino acids from identified peptides divided by the number of amino acids in the primary sequence 
of the protein.  













3.10.1 Functional annotation of differentially expressed proteins in 
DNPH1 knockdown 
Functional annotation of the differentially expressed proteins were performed 
using Uniprot-GOA [82] as described previously in Section 3.2.3. Proteins 
involved in metastasis are one of the main groups being regulated by DNPH1 
knockdown, which mirrors the decrease in both migration and invasion in KD 
cells as observed experimentally (Sections 3.7 and 3.8). In addition, proteins 
involved in lipid metabolism, redox mediators and electron transport chain 
proteins had been previously implicated in the progression of HCC. The 
correlation between these proteins and HCC progression will be discussed in 
detail in Section 4.5.2.         
 
Figure 3-13: Functional annotation of differentially expressed proteins in KD 
cells. The differentially expressed proteins in DNPH1 knockdown cells were 
annotated as described in Section 3.2.3. Proteins involved in lipid metabolism, 
metastatic processes, redox mediation and ETC complex assembly (bars in red) will 





3.11 Western blot validation of iTRAQ data  
A total of 4 proteins were chosen for western blot validation to confirm the 
altered expression of proteins resulting from DNPH1 silencing. These proteins 
belong to the metastasis related proteins and redox mediators respectively. In 
addition, DNPH1 expression of the cell lines used in iTRAQ was checked via 
western blot. The successful validation of these protein targets via western blot 
clearly demonstrates the reliability of iTRAQ quantitation, and provides 
greater confidence of the involvement of these proteins in mediating the 
functional differences resulting from DNPH1 knockdown.  
 
 
Figure 3-14: Western blot validation of iTRAQ results. Selected proteins 
regulated by DNPH1 silencing were validated by western blotting in the cell lysates 







CHAPTER 4 DISCUSSION 
 
4.1 Biomarker discovery of prognostic biomarkers for HCC 
recurrence   
The prognosis of HCC patients remains poor due to the high recurrence rate 
after curative treatment. The recurrent tumours of patients with early 
recurrence usually develop into stage IV metastatic tumours, resulting in much 
lower survival rate compared to patients with late or no recurrence [25, 26]. 
Prognostic biomarkers for prediction of early recurrence might aid in the 
clinical management of early HCC patients who are amenable for curative 
treatment, as well as development of novel therapeutics for prevention of 
recurrence. In this study, we utilized an iTRAQ 2D-LC MS/MS to profile the 
proteome of paired tumour and adjacent non-tumour liver samples of stage I 
HCC patients to identify biomarkers that can segregate these patients 
according to their recurrence status. To determine proteins that can distinguish 
patients between the early recurrence and non-recurrence group, we sought to 
identify proteins that were consistently regulated in the tumours of patients 
within each group, before comparing the fold change in regulation of these 
proteins within the two groups. These proteins were subjected to two levels of 
validation: SWATH-MS validation to validate iTRAQ results; and western 
blot to validate the consistency in regulation patterns observed in iTRAQ in a 





4.1.1 Analysis of individual samples versus pooled samples   
Previous LC-based quantitative proteomics studies in identification of 
prognostic biomarkers for HCC recurrence relied on the use of pooled tissue 
lysates of tumour versus adjacent non-tumour tissue during the discovery 
phase [70, 72]. Pooling of samples would reduce the amount of sample and 
time taken for proteomic analysis of the tissue lysates, especially if the number 
of samples to be analysed is huge. However, pooling of samples results in the 
loss of information of the biological variation among individuals. Results may 
also be skewed if the expressions of certain proteins are in the extremities for 
certain individuals. Lastly, to obtain biologically relevant information from 
pooled samples, the groups must be as homogenous as possible, which 
requires a lot of clinical information and background knowledge of the HCC 
pathogenesis in individual patients within the group. Analysis of the proteome 
of individual patients would require more samples and time, however the 
variation between individuals may allow us to observe subgroups within the 
designated groupings in the initial study design. HCC is a heterogeneous 
disease in which the pathophysiology is not well understood. It may be 
difficult to obtain a homogenous group simply based on clinical information 
that is available for each patient. Hence, we adopted the approach to analyze 
the proteome of the tumour and adjacent non-tumour tissue of each individual 
patient, of which the T/N ratio was obtained for each protein to “normalize” 
for individual variations. To achieve a balance in the time and cost of the 
experiment, we analyzed the proteome of 9 individuals, in which 4 are from 




4.1.2 Allocation of samples in the different iTRAQ experiments   
The iTRAQ technology allows the analysis of up to 8 different samples in a 
single analysis. A total of 2 different samples, namely the liver tumour and the 
adjacent non-tumour lysate, were available for each patient. Hence, a 
minimum of 3 iTRAQ runs was necessary to cover the proteome of 18 tissue 
lysates from 9 individual patients. When assigning the samples for iTRAQ run, 
two main issues were considered: (i) The tumour and adjacent normal tissue 
lysate for each individual must be analyzed in the same iTRAQ run; (ii) each 
iTRAQ run must consist of at least 1 sample from each group. These two 
considerations take into account of the inter-run variations between different 
iTRAQ runs, as well as the possibility of skewed distribution of proteins 
within each group that might bias the identification of proteins in each run.  
4.1.3 Low number of common proteins identified among three different 
iTRAQ experiments   
From each iTRAQ run, we obtained an average of 2335 proteins identified 
using unused score of 1.3.  Only 1191 proteins were consistently identified in 
all 3 independent iTRAQ experiments. This may be due to the variation of 
protein expression in different individuals, as well as the under-sampling of 
low abundance proteins by the detection method. The data acquisition method 
used in iTRAQ analysis is based on information dependent acquisition, in 
which the precursor ions with relative intensity over a set threshold level will 
be selected for subsequent MS/MS analysis to provide information on the 
identity of the peptide [87]. Low abundant peptides may be masked if they 
were eluted from the LC together with the peptides from the high abundant 
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proteins. Furthermore, there are situations where multiple isoforms are present 
for a target protein. The identities of the protein are assigned based on the 
presence of unique peptides that can distinguish the individual isoforms. 
Hence, it is possible that the increased abundance of any protein will result in 
the successful identification of the particular isoform in a particular iTRAQ 
experiment, which might not be observed in other iTRAQ experiments due to 
the lower abundance.                     
4.1.4 Application of SWATH-MS for validation  
In the discovery phase using iTRAQ technology, a total of 52 proteins were 
identified to be differentially expressed between the tumours of ER and NR 
HCC patients. Validation of protein expression changes is necessary to 
confirm the expression patterns observed in the iTRAQ experiment. Western 
blot is commonly used as an orthogonal method for verification of protein 
expression due to the ease of application. However, it is difficult to verify the 
expression of all 52 proteins due to the cost and availability of commercial 
antibodies, as well as the limited amount of tissue lysates available for 
validation purposes. Hence, a SWATH-MS based validation step was included 
in our study. Despite the use of mass spectrometer as the detection tool, 
SWATH-MS can be considered to be distinct from IDA analysis used in 
iTRAQ due to the differences in data acquisition and method of peptide 
quantitation. SWATH-MS validation has the following advantages over 
western blot: (i) A smaller amount of sample is required for SWATH-MS 
analysis for validation of a larger number of protein targets and (ii) SWATH-
MS creates a digital archive of the protein expression levels in the complex 
sample which allow for retrospective comparison. Despite these advantages, 
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the amount of LC-MS time required to perform the SWATH-MS experiments 
is relatively huge. Hence, SWATH-MS analysis was only performed on the 
tissue lysates of samples used in iTRAQ analysis for validation purposes.  
From the SWATH-MS analysis, we have successfully validated the expression 
of 12 of the 52 differentially expressed proteins identified in iTRAQ. The low 
number of proteins that overlap in expression patterns between the 2 methods 
could be attributed to the different LC separation of the samples. For the 
iTRAQ analysis, a 2D-LC separation combining SCX and RP separation was 
performed while a single RP separation was employed for SWATH-MS 
analysis. Increased separation of the peptide mixture by 2D-LC lowers the 
sample complexity, allowing for more peptides to be analysed and identified 
within the limits of detection by MS. Nonetheless, the successful verification 
of expression levels of the 12 differentially regulated proteins by SWATH-MS 
provides additional confidence of the iTRAQ data and narrowed the choice of 
biomarker candidates for subsequent validation in a larger cohort of patients 
by western blot. 
4.2 Comparison between differentially expressed proteins identified in 
DIGE versus iTRAQ 
Previously, using a 2D-DIGE approach,  Tan et al  showed an upregulation of 
HSP70, TKT and downregulation of ASS1 and UGP2 in the tumours of ER 
patients compared to NR patients [77]. However, only HSP70 was identified 
in our study to be differentially regulated between the 2 groups. The other 
three proteins, TKT, ASS1 and UGP2 were identified in all 3 iTRAQ 
experiments. Although the expression patterns of these three proteins within 
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the paired tissue lysates of individual patients followed similar trends as 
previously observed [77], the difference in the average T/N ratio between the 
two patient groups did not meet the cutoff in the current study. This may be 
due to the small number of patient samples used. The average T/N ratios for 
these three proteins can be found in the appendix (Appendix IV). Thus, in 
general, the iTRAQ results observed in our study corroborated with the 2D-
DIGE results. In addition, we managed to validate 2 new potential biomarkers 
for prognosis of HCC in our study, namely DNPH1 and HSP10.       
4.3 Functional relevance of differentially expressed proteins in 
tumours of Early Recurrence patients 
From the list of dysregulated proteins, we have identified key changes in 
protein expression patterns within the tumours of early recurrence patients that 
differ from non-recurrence patients (Figure 3-4). These changes include the 
increased expression of heat shock proteins and changes in expression of 
multiple proteins involved in cellular metabolism. Understanding the 
molecular changes in the tumours of early recurrence patients would allow for 
design of novel treatment strategies in an effort to decrease the chance of 
recurrence. In the following section, we will discuss the relevance of these 
proteins in cancer progression and metastasis, with emphasis placed on 






4.3.1 Overexpression of heat shock proteins  
Heat shock proteins (HSP) are molecular chaperones that promote proper 
folding and localization of proteins [88], thus promoting survival of cells 
during stress. In our study, the expression levels of HSP10 and HSP70 were 
increased in tumours of early recurrence patients. Overexpression of HSP10 
has been previously reported in large bowel [89-91], ovarian [92] and HCC 
[93]. HSP10 has been suggested to modulate tumourigenesis by inhibiting 
apoptosis [94] and modulating immune response [92]. Localization of HSP10 
might also play a role in tumour promotion, in which secretion of HSP10 is 
required for its suppression of immune response [92]. The mitochondrial 
protein HSP10 has also been found to accumulate in the nucleus [95], however, 
its function in the nucleus remains to be elucidated.  The increased expression 
of HSP10 in tumours of early recurrence patients was validated via western 
blot, which concurred with the observation made by Ye et al [93]. However, 
the exact role of HSP10 in HCC progression remains unclear.      
HSP70 is a well-studied heat shock protein in which increased expression 
correlates with poor clinical outcome of different cancers, including HCC [96-
99] . In particular, our lab has previously demonstrated the clinical utility of 
HSP70 overexpression in HCC tumours to predict early recurrence [77]. 
HSP70 is involved in promoting tumour progression by inhibiting apoptosis 
through interaction with BAX [100], APAF-1[101], death receptors [102], 
apoptosis-inducing factor [103] and stress related signaling kinases [104, 105]. 
Additionally, HSP70 regulates multiple cancer signaling pathways through its 
interaction with cochaperone Bag3 [106]. Silencing HSP70 results in growth 
inhibition [107, 108] and apoptosis of cancer cells [109], including HCC [110]. 
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Hence, HSP70 is an attractive target for development of cancer therapeutics, 
which might potentially be used for prevention of HCC recurrence.   
4.3.2 Changes in expression of metabolic proteins   
Majority of the proteins that are found differentially expressed in our study are 
metabolic proteins. Dysregulation of metabolism has recently been included as 
a hallmark of cancer in cancer progression [111]. Changes in metabolic 
proteins might also reflect the loss of liver function due to dedifferentiation of 
the tumour cells in HCC progression [112]. In our study, perilipin-2 (PLIN2) 
and Arginase-1 (ARG1) were identified to be dysregulated to a greater extent 
in the tumours of early recurrence patients (validated by SWATH-MS). 
Perlipin-2 is a lipid droplet associated protein that is crucial for formation and 
maintenance of lipid droplets in cells [113, 114]. Increase in lipid droplets are 
commonly observed in steatosis and HCC [115] due to activation of 
lipogenesis during HCC development [116]. Increased lipid droplet formation 
has been implicated in tumorigenesis by promoting cell proliferation [117], 
metastasis [118] and inflammation [119]. PLIN2 levels may thus be regarded 
as a surrogate marker and therapeutic target for HCC through its involvement 
in HCC progression. 
Arginase-1 is a liver-specific enzyme in the urea cycle that catalyzes the 
breakdown of arginine to ornithine and urea. Ornithine can be recycled back to 
arginine via the urea cycle through the enzymatic reactions catalyzed by 
ornithine carbamoyltransferase, argininosuccinate synthetase and 
argininosuccinate lysase.  This provides a means of maintaining the 
intracellular levels of arginine, which is involved in multiple biosynthetic 
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pathways, such as nitric oxide, nucleotide, proline and glutamine biosynthesis 
[120].  HCC tumours are usually auxotrophic for arginine due to the reduced 
expression of argininosuccinate synthetase (ASS1) [121], and the concomitant 
decrease in expression of ARG1 may be necessary to maintain intracellular 
arginine levels by decreasing arginine catabolism. Arginine may be converted 
to nitric oxide, which promotes the maintenance of cell progenitor 
characteristics and increase in chemoresistance to sorafenib in HCC cells 
[122]. Decrease in ARG1 levels were also correlated with increased 
aggressiveness and recurrence of HCC, as well as lowered survival patients 
[123]. Hence, the decreased expression of ARG1 and ASS1 [77] in the 
tumours of early recurrence patients observed in the iTRAQ and 2D-DIGE 
studies may be a good prognostic marker for indicating aggressiveness of the 
tumour in HCC patients. Patients with lowered ARG1 and ASS1 levels may 
be more responsive to recombinant human arginase treatment, which was 
efficacious in causing HCC remission in vivo [124, 125]. The safety profile 
and optimal dose of pegylated recombinant human Arginase 1 was determined 
in the phase I clinical trial on advanced HCC patients [126] and recruitment of 
patients for phase II clinical trial are currently ongoing. Recombinant human 
Arginase I might emerge as a suitable treatment option for patients with early 
recurrence.                       
4.4 DNPH1 upregulation in Early Recurrence patients 
2’-Deoxynucleoside 5’-phosphate N-hydrolase 1 (DNPH1) was initially 
identified as a putative c-Myc responsive gene responsible for promoting 
cellular growth and transformation when coexpressed with either vascular 
endothelial growth factor (VEGF) or lactate dehydrogenase in Rat1a cells [127, 
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128]. The increased expression of DNPH1 has been reported in many different 
cancers, such as prostate [129], lymphoma [130-132], breast [133] and gastric 
[134] cancer. As such, DNPH1 has been recognized as a growth-related 
oncogene and a potential target for anti-cancer therapies. Previous studies on 
DNPH1 have focused on elucidating its catalytic action and structure. DNPH1 
catalyzes the hydrolysis of N-glycosidic bond of deoxyribonucleoside 5’-
monophosphates from deoxyribose 5’-phosphate and the free base, with higher 
affinity for purine nucleotides. The reaction catalyzed by DNPH1 has been 
proposed to promote cellular growth by supplying the free base to salvage 
pathways and diverting deoxyribose 5’-phosphate into the glycolytic pathway 
for energy production [135]. Subsequently, the elucidation of DNPH1 solution 
[136, 137] and crystal structures [138], together with the understanding of 
nucleotide binding and catalytic mechanism by site-directed mutagenesis [139, 
140] allowed for the design of small molecules that target the active site of 
DNPH1. Indeed, Amiable and colleagues had demonstrated that N6-
substituted adenosine 5’-monophosphate derivatives [141] and 6-
(Hetero)Arylpurine nucleotides [142] act as competitive inhibitors of DNPH1 
with inhibitory constants within the micromolar range. In addition, 6-
(Hetero)Arylpurine nucleotides have been shown to inhibit the growth of 
lymphoma and colorectal cell lines [142], supporting the notion of DNPH1 
inhibition in cancer therapy.  
Despite the numerous studies on the structure and catalytic function of 
DNPH1, there is no experimental evidence for its role in cancer development. 
Previous studies had only demonstrated a correlation between DNPH1 
expression and cancer progression [129-133]. The results from our iTRAQ 
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study indicated that there is a higher increase in DNPH1 expression in the 
tumours of early HCC recurrence patients compared to non-recurrence 
patients, and this was confirmed by western blotting of tissue lysates from a 
larger cohort of HCC patients. c-Myc amplification is often observed in HCC 
patients [143], especially in the more advanced cases [144]. Furthermore, c-
Myc plays an important role in the malignant transformation of dysplastic 
nodules to early HCC in cancer development [145]. The action of c-Myc in 
HCC progression may be partially mediated by DNPH1. The gap in 
knowledge of DNPH1 expression in cancers, coupled with the possibility of 
DNPH1 mediating HCC recurrence as shown in this study, prompted us to 
study the possible biological function of DNPH1 in HCC via in vitro studies.  
4.5 Analysis of DNPH1 function in vitro using HCC cell lines   
The protein levels of DNPH1 in three different HCC cell lines were checked 
using western blot. Among them, Hep3B has the highest expression level of 
DNPH1. HCC recurrence is often correlated with the presence of vascular 
invasion [26-29], which is an indication of high metastatic ability of the 
primary tumour. Additionally, DNPH1 has been implicated as a growth-
related oncogene [127, 128]. Hence, we focused our study on elucidating the 
role of DNPH1 in cell migration, invasion and proliferation in HCC through 
the use of Hep3B cell lines with stable DNPH1 knockdown.            
4.5.1 DNPH1’s role in regulation of cell migration, invasion and 
proliferation in vitro 
The role of DNPH1 in regulating cellular migration and invasion was 
demonstrated via a series of in vitro experiments. Our data showed that 
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DNPH1 knockdown inhibits the migration and invasion of Hep3B cells 
(Figures 3-9 to 3-11). This is the first study that demonstrated the correlation 
of DNPH1 expression with metastatic potential of cancer cells. The increase in 
DNPH1 expression in the liver tumours of early recurrence HCC patients 
might thus promote the gain of a metastatic phenotype of remnant tumour cells, 
resulting in early recurrence which would manifest as intrahepatic metastasis 
or even metastasis to other organs. Our study also shows that DNPH1 
knockdown did not affect the proliferation rate of Hep3B cells (Figure 3-12). 
This is in contrast with the existing literature that classified DNPH1 as a 
growth-related oncogene. DNPH1 expression was increased in regenerating 
rat liver after partial hepatectomy [127]. However, rat DNPH1 contains a 
nuclear targeting sequence which is absent in human DNPH1 [127].  The 
difference in localization of rat and human DNPH1 was confirmed by 
immunofluorescence in previous studies, in which DNPH1 was localized in 
the nucleus in Rat1a cells [127], but found in the cytoplasm in breast cancer 
cells [133]. Thus, the function of DNPH1 might change according to its 
cellular localization. SiRNA knockdown of DNPH1 resulted in decreased 
growth of human gastric cancer cell lines HSC58 and HSC60 [134]. However, 
the effects of DNPH1 knockdown may be cell type specific, and more studies 
need to be performed to confirm this. Nonetheless, in our study, stable 
knockdown of DNPH1 results in a decrease in invasive and migratory 





4.5.2 Proteomics identification of downstream processes regulated by 
DNPH1 
The current literature on DNPH1 is limited to the understanding of its 
structure, catalytic mechanism and correlation of expression to different 
cancer types. There are currently no studies on the biological function of 
human DNPH1 in cancer. This makes it difficult to study the probable 
biological significance of DNPH1 expression in cancer cells through a 
hypothesis based approach. As such, we utilized a quantitative proteomics 
approach to generate new hypothesis in unravelling the biological effects 
modulated by DNPH1. Identification of proteins that are differentially 
expressed between the KD and SC cells allow us to map out core pathways 
that are mediated by the change in DNPH1 expression, which could be linked 
to the phenotypic changes that were observed in the different studies reported 
in existing literature. The iTRAQ experiment had identified a total of 56 
differentially expressed proteins. Proteins involved in metastatic processes 
belong to one of the major protein clusters that are differentially regulated by 
DNPH1 knockdown. Other groups of proteins that might be involved in HCC 
progression include proteins in lipid metabolism, redox mediation and electron 
transport chain complex formation (shown in red in Figure 3-13). The 
involvement of these clusters of proteins in HCC progression will be discussed 





4.5.2.1 DNPH1 knockdown affects the expression of metastasis-related 
proteins involved in formation of invadopodia 
Metastasis is a multistep process which involves the invasion of cells across 
the extracellular matrix, entry and exit from the circulation and colonization of 
a distant organ [146]. Invadopodia are finger-like protrusions that form on the 
ventral side of the cancer cells [147]. These structures facilitate the migration 
of cancer cells in a three stage process. Firstly, the initial formation of 
invadopodia results in perforation of the basement membrane. Subsequently, 
the maturation of invadopodia results in the elongation of this structure deeper 
into the stromal compartment. Metalloproteases are secreted by the 
invadopodia to facilitate the elongation process. Eventually, the invadopodia 
breaks through the extracellular matrix resulting in migration of cells [148]. 
We found that DNPH1 knockdown affects the expression of proteins involved 
in the initial formation and maturation of invadopodia, which will be discussed 





Figure 4-1: Cytoskeletal rearrangements in invadopodia formation and 
maturation. The initial formation of invadopodia requires both the branched and 
bundled actin network (1a). The subsequent elongation of invadopodia is performed 
by the extension of the bundled actin network, which is supported by the branched 
actin network at the base (1b, 2a). Once the invadopodia matures to a critical length, 
its integrity is maintained by the microtubules and intermediate filaments. The actin 
bundles are also replaced by the branched actin network. Figure adapted from 
Schoumacher et al, 2010 [148].  
 
The cytoskeletal changes that happened during invadopodia formation are 
illustrated in Figure 4-1. The initial formation of invadopodia involves the 
formation of focal adhesions to the extracellular matrix through interactions 
with integrins. This leads to the activation of signaling pathways that result in 
the recruitment and stabilization of the actin network [149]. The changes in 
actin network involve the formation of the branched actin network of the 
lamellipodia supporting a rod-like protrusion formed by the stiff, tightly 
bundled actin network of the filopodia. The formation of the long, parallel 
actin fibres observed in filopodia requires the protection of barbed actin ends 
from capping by actin capping proteins such as CAPZA2. [150].  The 
stabilization of the protrusion is also mediated partly by RRAS, which is 
activated by integrins and results in directional formation of protrusions 
88 
 
through Rho signalling [151]. Increased CAPZA2 and decreased RRAS 
expression in DNPH1 KD cells result in the inhibition of invadopodia 
formation by modulating the expansion of the branched actin network, 
decreasing the probability of formation of bundled proteins.  
The maturation of the invadopodia involves the secretion of proteases to 
degrade the extracellular matrix, in combination of the protrusion force 
provided by the branched actin network. Intermediate filaments enter the 
invadopodia only at the maturation stage [148]. These filaments form 
networks that provide mechanical strength to stabilize and prevent the collapse 
of the invadopodia structure. Protein expression levels of flotillin-2, 
cytokeratin-19 and vimentin were downregulated in DNPH1 knockdown cells. 
Flotillin-2 is a scaffolding protein that is localized on lipid rafts. These 
structures are implicated in modulating signaling pathways and form sorting 
platforms for trafficking of proteins to its targeted destination [152]. Increase 
in Flotillin-2 expression has been associated with worse prognosis in breast 
[153, 154], renal [155], melanoma [156] and gastric [157] cancers. Flotillin-2 
has been shown to interact with kinesin KIF9 in Flotillin-2/Flotillin-1/KIF9 
complex, which modulates matrix degradation in podosomes [158]. 
Podosomes are structurally similar to invadopodia, except that they are formed 
on non-cancerous cells, such as dendritic cells [159]. Decrease in Flotillin-2 
expression may inhibit invadopodia maturation by damping various signaling 
pathways. The reduction in production of proteases may also reduce the speed 
of invadopodia elongation, thus reducing the metastatic potential of the cancer 
cells. Cytokeratin-19 and vimentin are intermediate filaments that are involved 
in invadopodia maturation [148, 160] . Decreased expression of cytokeratin-19 
89 
 
and vimentin limits the extent of elongation of invadopodia, resulting in 
decreased cell invasion. In addition, cytokeratin-19 and vimentin have been 
implicated in increased metastatic potential of tumours [161, 162], through 
their roles in epithelial-mesenchymal transition [163] and association with a 
progenitor cell phenotype [164] in HCC. Overall, the changes in expression of 
metastatic related proteins may result in the decreased formation and 
elongation of invadopodia, which could explain the decreased invasive 
properties of KD cells as observed in matrigel invasion assay (summarized in 
Figure 4-2).  
 
 
Figure 4-2: DNPH1 knockdown affects invadopodia formation and 
development. The flowchart summarizes the changes in expression of different 
metastasis-related proteins in affecting invadopodia formation and maturation as 
identified in iTRAQ. Proteins upregulated and downregulated in KD cells are shown 




4.5.2.2 DNPH1 knockdown results in increased expression of proteins 
involved in the electron transport chain           
Mitochondrion is the powerhouse of the cell and is the main source of ATP 
production through oxidative phosphorylation (OXPHOS). In our iTRAQ 
results, we detected an upregulation of COX7A2, a subunit of cytochrome C 
oxidase, as well as COA3 and UQCC3, which are involved in the assembly of 
cytochrome C oxidase and ubiquinol-cytochrome C reductase complex 
respectively. These proteins are involved in the formation of complex III and 
complex IV of the electron transport chain (ETC), which participate in the 
transfer of electrons from oxygen via cytochrome C with the translocation of 
protons across the inner mitochondria membrane. Among the different 
complexes in the electron transport chain, complex IV is one of the most 
important complexes for the proper functioning of OXPHOS due to its role as 
the terminal oxidase for transfer of electrons to oxygen [165]. This is 
highlighted in several studies in which the presence of complex IV is essential 
for the assembly [166] and phosphorylative activity of the electron transport 
chain [167]. Hence, the increased expression of subunits of complex IV and 
proteins involved in assembly of complex III and IV may indicate the proper 
functioning of the electron transport chain in the mitochondria. 
The association between dysfunctional mitochondria and cancer has been well 
established [168], which is based on the decreased amount of ETC complexes, 
resulting in reduced OXPHOS. Decreased OXPHOS is also linked to tumour 
aggressiveness, where aggressive cancer cells prefer the use of glycolysis and 
glutaminolysis for ATP generation. In addition to ATP, both glycolysis and 
glutaminolysis supply intermediates for synthesis of biomolecules to support 
91 
 
the growth of cells. This provides a survival advantage over the use of 
OXPHOS, which only generates ATP, albeit at a much higher efficiency 
compared to glycolysis and glutaminolysis. The inverse correlation between 
tumour aggressiveness and OXPHOS has been demonstrated in renal cell 
carcinoma [169], colorectal cancer [170] and ovarian cancer [171].  Hence, the 
increased expression of mitochondrial complexes might promote the shift in 
DNPH1 KD cells towards the use of OXPHOS, which might be linked to its 
decreased metastatic potential.   
Decreased expression of mitochondrial complex has also been linked to the 
development of cancers. Patients with liver mitochondrial respiratory chain 
disorders have an increased propensity to develop HCC [172]. Furthermore, 
decreased complex IV subunit 1 and VII expression is correlated with poor 
prognosis for HCC and Barrett’s adenocarcinoma respectively [173, 174]. 
Interestingly, the activation of oxidative phosphorylation overcomes the 
resistance of HCC to sorafenib [175]. Overall, an increase in amount of 
complexes of the electron transport chain may result in increased functionality 
of electron transport chain, decreased aggressiveness and progression of HCC 








4.5.2.3 DNPH1 knockdown results in changes in lipid metabolism 
Hepatic steatosis is one of the prominent features of HCC and the storage of 
these neutral lipids in the cell body has been implicated in the pathogenesis of 
HCC [176]. A change in expression of proteins involved in various aspects of 
lipid metabolism was observed in DNPH1 KD cells. A decreased expression 
of proteins involved in lipid synthesis (LSS and CYB5B), accompanied by 
increased expression of proteins involved in activation (ACSS3 and PECR) 
and transport of free fatty acids (FABP1 and DBI), suggest a metabolic shift 
towards catabolism of lipids through β-oxidation. Bioinformatics analysis 
predicted that the regulation of the above-mentioned proteins might be 
mediated by peroxisome proliferator activated receptor alpha (PPARα). 
PPARα is a transcription factor belonging to the subgroup of nuclear hormone 
receptor superfamily [177]. PPARα acts as a lipid sensor in the liver and 
responds to high fatty acid influx. Activation of PPARα involves the 
dimerization with retinoid receptor and binding to peroxisome proliferator 
response elements, resulting in promoting expression of downstream genes. 
These downstream genes are involved in regulating lipid metabolism and 
inflammatory responses, which are often dysregulated in HCC. PPARα 
increases lipid catabolism by increasing expression of enzymes involved in β-
oxidation in the mitochondria and peroxisomes, as well as transport proteins 
involved in binding and uptake of free fatty acids [178]. Decreased PPARα 
protein expression has been widely implicated in promoting hepatic steatosis, 
which is often reversed by application of PPARα agonists [179]. PPARα 
expression has also been inferred to be downregulated in early recurrence of 
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HBV-positive HCC patients in a transcriptomics study [180], which could be a 
result of the downregulation of β-oxidation machinery in HCC patients.  
Many studies have demonstrated the anti-tumourigenic and anti-angiogenic 
effects of PPARα activation on cancer cells through the use of PPARα 
agonists. These include inhibition of VEGF production [181], the suppression 
of HIF-1α signaling in breast cancer cells [182] and decreased proliferation 
and tumourigenesis of ovarian cancer cells [183]. The effects of PPARα 
activation on HCC cell lines have also been widely studied. Activation of 
PPARα by addition of pharmacological agonists results in apoptosis of SK-
Hep-1 [184] and HepG2 cells [185]. In addition, the crosstalk between PPARα 
and inflammatory pathways mediated by cytokines plays an important role in 
hepatocarcinogenesis. IL-6 and TNF-α inhibit the protein expression of 
PPARα in HCC cell lines through induction of CCAAT/enhancer-binding to 
PPARα promoter [186] and activation of NF-κB pathway [187] respectively, 
while activation of PPARα prevents hepatocarcinogenesis by inhibition of NF-
κB pathway [188]. The balance in the levels of inflammatory cytokines and 
PPARα could thus determine the predominant signaling pathways in HCC 
cells, which could determine the malignancy of the cancer cells. Hence, we 
postulate that the activation of PPARα in DNPH1 KD cells could drive the 
cells towards a less malignant phenotype by decreasing steatosis and 
inflammatory signaling pathways. 
Lastly, we observed changes in proteins that mediate expression of pro- 
inflammatory lipids. Prostaglandin reductase 1 (PTGR1) possess both anti-
inflammatory and anti-oxidative properties through inactivation of eicosanoids 
such as Leukotriene-B4 (LTB4), and reduction of reactive lipid metabolites 
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[189, 190]. LTB4 is a pro-inflammatory lipid which acts as a chemoattractant 
for inflammatory cells and activates inflammatory pathways through binding 
to its receptor BLT2 [191]. In HCC, LTB4 promotes the activation of NF-κB 
pathway through increasing the expression of NF-κB p65 and modulating 
phosphorylation of the inhibitor κBα [192]. In addition, LTB4, being one of 
the main metabolic products of 5-lipooxgenase (5-LOX), may be involved in 
the promotion of HCC migration through the crosstalk of signaling pathways 
involving NF-κB, 5-LOX, osteopontin and calpain small subunit 1 [193]. Thus, 
increased metabolic inactivation of LTB4 through upregulation of PTGR1 
expression may prevent HCC progression via attenuation of LTB4-mediated 
NF-κB signaling.         
4.5.2.4 DNPH1 knockdown results in changes in expression of redox 
mediators 
The redox environment of a cell is defined as the sum of products of reduction 
potential and reducing capacity of redox couples present [194]. This is 
maintained by the endogenous anti-oxidative proteins that catalyze the 
removal of reactive oxygen species. These proteins require reducing 
equivalents such as NADPH for proper functioning of catalytic activity. The 
reduction potential of HCC tissues is usually low and is characterized by the 
decrease in the amount of anti-oxidant proteins [71, 74, 112] and increased 
concentration of free radicals as a result of dysfunctional complexes of 
electron transport chain and inflammatory cytokines. Decreased levels of 
peroxiredoxin-2 were also observed in the tumour tissues of patients with 
early recurrence in our study (Tables 3-1 and 3-2). The subsequent increase in 
oxidative stress is associated with promotion of metastasis [195] and 
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angiogenesis [196] in HCC. Furthermore, patients suffering from HCC 
recurrence present a higher amount of ROS derivatives, suggesting the link 
between chronic oxidative stress and HCC recurrence [197, 198].  We 
observed an increase in cytosolic anti-oxidative proteins (Thioredoxin and 
NQO1) and enzymes that generate reducing equivalents (IDH1 and TKT) in 
DNPH1 KD cells. The thioredoxin system is one of the major redox systems 
involved in maintaining the redox status of the cell. The mechanism of action 
of the thioredoxin system involves the reduction of disulfides in oxidized 
cellular proteins by thioredoxin, which gets oxidized in the process. 
Regeneration of reduced thioredoxin is then catalyzed by the thioredoxin 
reductase, using NADPH as the electron donor [199]. NQO1 is a cytosolic 
protein that competes with cytochrome P450 reductase in the reduction of 
quinones and derivatives, reducing the production of free radicals [200]. The 
decrease in NQO1 levels is often observed in HBV-positive HCC [201-203] 
and is associated with increased mitochondrial injury, which impedes the 
proper functioning of the electron transport chain in HCC cells [203]. Hence, 
the increase in anti-oxidant proteins and NADPH production observed in 
DNPH1 KD cells might result in the decreased malignancy of cells by i) 
protecting against mitochondrial injury by ROS and its derivatives and ii) 
interfering with redox mediated signaling of inflammatory and metastatic and 






4.5.2.5 Crosstalk between proteins involved in redox modulation, lipid 
metabolism and mitochondrial function may regulate inflammatory 
signaling in HCC 
Existing literature suggests that there is extensive crosstalk between proteins 
involved in redox modulation, lipid metabolism and mitochondrial function in 
cancer. Decreased expression and functionality of electron transport chain 
complexes in the mitochondria of tumour cells result in the leakage of 
electrons from these complexes, which promote the formation of ROS. The 
removal of ROS is performed by the endogenous anti-oxidant enzymes, which 
are often downregulated in HCC [71, 74, 112]. In addition, inflammatory 
cytokines induce inflammatory signaling pathways by using ROS as second 
messengers. Thus, an accumulation of ROS is often observed in HCC tumours. 
Lipogenic pathways are activated in HCC, resulting in an increase in 
intracellular lipid levels [116]. These lipids can be oxidized by ROS, and the 
lipid peroxidation products would promote further mitochondrial dysfunction 
[204]. Mitochondrial dysfunction may result in the decrease in β-oxidation, 
which leads to an increase in lipid concentration in the cytoplasm [205]. This 
creates a positive feedback cascade which result in the consistent production 
of ROS and activation of inflammatory signaling pathways such as NF-κB 
pathway. ROS and NF-κB play important roles in HCC metastasis through 
promoting invadopodia formation [206] and metalloprotease production [207] 
respectively. In addition, ROS induces DNA damage which might lead to an 
accumulation of genetic aberrations and expression of malignant traits that are 
observed in progressed HCC tumours. Our iTRAQ results suggest that 
DNPH1 KD results in increased anti-oxidant proteins, electron transport chain 
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complex formation and decreased lipid concentration, which might result in 
disruption of the inflammatory phenotype, thus preventing HCC progression.    
4.5.2.6 Proposed model of DNPH1 silencing suggests its potential as a 
target in preventing HCC recurrence  
HCC progression is characterized by the chronic inflammatory state, which 
provides the environment for accumulation of genetic aberrations and 
acquisition of malignant traits. Additionally, early recurrence is often 
associated with the presence of vascular invasion, which is a clear indication 
of the increased metastatic potential of the primary tumour. Hence, adjuvant 
treatments which limits the metastatic potential of undetected HCC cells and 
relieves the liver from its pro-inflammatory state might be useful in preventing 
HCC recurrence.  
Based on the iTRAQ results, we have proposed a model of the possible 
biological functions of DNPH1 in HCC cells. We showed that silencing 
DNPH1 decreases the aggressiveness of Hep3B cells by modulating the 
expression of proteins that are implicated in metastasis and invadopodia 
formation. Furthermore, silencing of DNPH1 may lead to a recovery of 
mitochondrial function, maintenance of redox balance in the cellular 
environment, as well as a shift towards lipid catabolism. These metabolic 
processes are interlinked, and dysregulation of these processes results in the 
formation of a pro-inflammatory state in cancer. Thus, DNPH1 might be an 
attractive target for prevention of HCC recurrence through its role in 






Figure 4-3: Proposed model of DNPH1 knockdown in HCC. DNPH1 knockdown inhibits metastasis and promotes the increase in 
expression of redox mediators, and electron transport chain complexes. In addition, there is a shift towards lipid catabolism. The change in 
metabolism (large circle in blue) may inhibit ROS mediated inflammation cycles, which would inhibit HCC progression and development of 
metastatic phenotype. Targets upregulated and downregulated by DNPH1 silencing are indicated in red and green respectively.   
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CHAPTER 5 LIMITATIONS OF CURRENT STUDY 
In this study, we had used iTRAQ-based quantitative proteomics to interrogate 
the proteome of paired tumour and non-tumour liver tissue lysates to identify 
potential biomarkers for stratification of stage I HCC patients based on 
recurrence status. DNPH1 expression was upregulated to a greater extent in 
the tumour of ER patients compared to NR patients. Cell-based assay 
demonstrated that knockdown of DNPH1 resulted in decreased metastatic 
potential of Hep3B cells. There are several limitations in the study, which will 
be addressed below:  
The first issue concerns the identification of commonly detected proteins in 
the three independent iTRAQ studies. In bottom-up quantitative proteomics 
studies, the proteins in the tissue lysates are first trypsin digested and labelled 
before separation and identification of the peptide sequence by LC-MS/MS 
analysis. The raw peptide sequences identified in the search are then assigned 
to different proteins in the protein database. However, there is redundancy in 
the protein database, in which multiple entries of a particular protein could be 
present in the database, but assigned with different accession numbers. This is 
especially true for different isoforms of the same protein, in which there might 
be minute differences in the primary sequences. Hence, proteins that might be 
present in all liver tissue lysates could be assigned with different accession 
numbers in the three independent iTRAQ experiments due to the abundance of 
the protein/peptides within each sample. Thus, using protein accession 
numbers to identify common proteins might underestimate the number of 
commonly identified and quantified proteins. The extent of underestimating 
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the number of common proteins could be circumvented by increasing the 
number of technical replicates for each iTRAQ experiment and pooling the 
results before protein identification and quantitation. However, this requires a 
huge amount of tissue lysates, which is the main limiting factor in the study. 
Alternatively, the raw data from all three iTRAQ experiments could be 
combined and searched against the protein database to generate a list of 
proteins that were identified in all three iTRAQ experiments. This list of 
proteins could be used to create a smaller database which would be used for 
searching the individual datasets from the different iTRAQ experiments. The 
above mentioned approach requires a server that is able to handle the large 
amount of data generated from three 2D-LC MS/MS experiments. We had 
previously attempted to perform this search. However, it was unsuccessful due 
to the limited capacity of the server. Hence, we decided on the use of 
accession numbers for identification of common proteins. Despite 
underestimating the number of common proteins, this method does not 
compromise on the confidence of the common proteins identified between the 
different experiments. 
The cell-based assays in this study were performed on Hep3B cells 
incorporating a specific shRNA sequence or scrambled cassette sequence. The 
use of shRNA in knockdown of gene expression could result in off-target 
effects, which might result in changes in the proteome that is unrelated to the 
expression of DNPH1. To increase the confidence of identification of proteins 
and pathways that are regulated by DNPH1 expression, we could generate 
additional stable knockdown cell lines using different shRNA sequences that 
target DNPH1. These cell lines could be subjected to iTRAQ analysis and 
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proteins and molecular pathways that are commonly perturbed could be 
attributed to DNPH1 expression with higher confidence. In addition, 
knockdown cell lines could be generated using different HCC cell lines. 
Comparisons between different cell lines could confirm the effects of DNPH1 
expression in HCC and identify potential cell line specific effects of DNPH1 











































CHAPTER 6 CONCLUSION AND FUTURE WORK 
Hepatocellular carcinoma remains as one of the deadliest cancers in the world 
despite improvements in diagnosis. This is partly due to the high recurrence 
rate in HCC patients who had undergone “curative” treatment for the primary 
tumour. The lack of prognostic power of the current staging systems and 
adjuvant treatments in preventing recurrence impedes the effective 
management of HCC patients in the clinic. Hence, in this work, we 
characterized the liver proteome of stage I HCC patients in an effort to 
identify potential biomarkers that can be used to predict the risk of early 
recurrence in these patients. A total of 52 proteins were identified to be 
differentially regulated in the tumours of early recurrence patients compared to 
non-recurrence tumours, of which DNPH1 and HSP10 expression were 
successfully validated by SWATH-MS and western blot. These two proteins 
have not been implicated in HCC recurrence previously and they might serve 
as potential prognostic biomarkers for HCC.  
In addition, functional characterization of DNPH1, previously implicated as a 
growth-related oncogene downstream of c-Myc, was performed in this study. 
DNPH1 knockdown results in a decrease in migration and metastasis of 
Hep3B cells. This is the first study that provides experimental evidence of 
DNPH1 involvement in cancer metastasis. To further elucidate the biological 
functions regulated by DNPH1, a quantitative proteomics experiment was 
performed on the DNPH1 knockdown cells. This experiment revealed the 
potential involvement of DNPH1 in regulating the expression of metastasis-
related proteins, as well as modulating metabolic changes associated with 
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promoting of pro-inflammatory environment, which may promote HCC 
progression. DNPH1 has been implicated as a potential target for cancer 
therapy, in which our study has provided further evidence to substantiate the 
above claim, especially for HCC. In addition, DNPH1 may also serve as a 
potential therapeutic target for adjuvant therapy aimed at prevention of HCC 
recurrence.  
Future work can be performed to strengthen the association of DNPH1 
expression with HCC recurrence, as well as performing functional validation 
of proteomic changes observed in the DNPH1 knockdown cells. Some of the 
possible experiments are as follows:    
(a) Tissue Microarray Analysis (TMA) of DNPH1 expression   
The expression level of DNPH1 could be determined on a larger panel of HCC 
tissues to further validate the relationship between DNPH1 expression and 
HCC recurrence. The incorporation of clinicopathological information of these 
HCC patients could also allow us to evaluate the correlation between DNPH1 
expression, disease-free survival rates and staging of patients.    
(b) Evaluation of mitochondrial function and OXPHOS in KD cells 
Our proteomics analysis suggested an increase in mitochondrial function and 
OXPHOS in KD cells. The mitochondrial function can be evaluated by 
measuring the mitochondrial membrane potential of the cell line using JC10 
fluorescence dye. An increase in membrane potential will result in an 
increased accumulation of JC10 in the mitochondria, which can be measured 
by the shift in emission wavelength from 520 nm to 570 nm. The increased 
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OXPHOS can be confirmed by comparing the oxygen consumption rate of the 
KD and SC cells using XF extracellular flux analyzer. 
(c) Evaluation of redox status in DNPH1 knockdown cells  
Change in redox status has also been proposed as one of the main pathways 
leading to decreased inflammation status in DNPH1 knockdown cells. The 
change in redox status can be evaluated by measurement of intracellular ROS 
concentration, (determination of 2’-7’dichlorofluoresin oxidation), amount of 
lipid peroxidation products (detection of thiobabituric acid reactive 
compounds) and assessment of activity of endogenous antioxidants 
(measurement of thioredoxin activity).   
(d) Effects of treatment with DNPH1 inhibitors  
DNPH1 has been touted as one of the candidate drug targets for cancer 
treatment, and inhibitors for DNPH1 had been designed [141, 142]. However, 
the effects of these inhibitors in HCC cells have not been evaluated. This can 
be achieved by monitoring the effects of inhibitor treatment in cell viability 
using MTT assay. We could also repeat the transwell migration and matrigel 
invasion assays to determine the effects of inhibitor treatment in migration and 
invasion of HCC cells respectively. Lastly, a proteomics study can be 
performed to map out biological changes that result from inhibitor treatment. 
The results obtained can complement the proteomics data generated through 
the use of DNPH1 knockdown cells to get a more comprehensive 
understanding of the potential effects of such small molecule drugs in 
treatment and prevention of HCC, as well as identifying the potential 




































Appendix I: Evaluation of actin expression in liver tissue lysates. 10 µg of 
proteins were separated on 12.5% resolving gels and transferred onto the PVDF 
membrane. The expression of actin was highly variable between different tissue 




Appendix II: Colloidal silver stained membrane of tissue lysates. 10 µg of 
proteins were separated on 12.5% resolving gels and transferred onto the PVDF 
membrane. Colloidal silver staining was performed such that the total protein amount 
can be used as a loading control. The sequence of loading is similar to the western 













Appendix III: Colloidal silver stained membrane of cell lysates. 10 µg of cell 
lysates from HepG2, Hep3B and PLC/PRF/5 were separated on 12.5% resolving gels 
and transferred onto the PVDF membrane. Colloidal silver staining was performed 
such that the total protein amount can be used as an alternative loading control since 






Appendix IV: T/N ratios of TKT, ASS1 and UGP2 in iTRAQ study. Similar 
expression trends of these proteins were observed in both 2D-DIGE and iTRAQ 





Non-Recurrence Early Recurrence 
Average 
T/N ratio G.S.D  
Average 
T/N ratio G.S.D  
P29401 TKT Transketolase 1.309 1.374 1.862 1.595 
P00966 ASS1 Argininosuccinate synthase 0.315 2.133 0.260 2.579 
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